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Abstract 
 
 
JING XU: Precisely Engineered Protein-Based PRINT® Particles for Delivery of 
Nucleic Acids 
(Under the direction of Professor Joseph M. DeSimone) 
 
RNA replicon (self-replicating RNA) has long been regarded as an 
important form of vaccines due to its remarkable immunogenicity and superior 
safety features. In this study, we report the first non-viral delivery of RNA 
replicons using protein-based PRINT particles. Cylindrical bovine serum albumin 
(BSA) particles (diameter (d) 1 µm, height (h) 1 µm) fabricated utilizing PRINT® 
technology were rendered transiently insoluble using a novel, reductively labile 
disulfide-based cross-linker.  After being cross-linked, the protein particles retain 
their integrity in aqueous solution and dissolve preferentially under a reducing 
environment which is found in cytoplasm, the site of action for RNA replicons. 
Our data reveal that the cross-linker leaves no chemical residue on the amino 
group it reacts with after being cleaved, which represents a great advantage over 
traditionally used protein cross-linkers. The particles were loaded with RNA 
replicons encoding several different proteins including Chloramphenicol Acetyl 
Transferase (CAT), green fluorescent protein (GFP) and Luciferase protein. The 
PRINT process used to fabricate protein-based particles in this study is gentle 
and avoids the obvious degradation of RNA replicons. The disulfide cross-linker 
is RNA-friendly and can stabilize the particles without affecting the biological 
iv 
performance of RNA replicons. Delivery of the particles to Vero cells was 
achieved by coating particles with a TransIT-mRNA transfection reagent 
(TransIT) and cationic lipids (DOTAP and DOPE). Our data suggest that: 1) it is 
necessary to use a degradable cross-linker for successful delivery of RNA 
replicon via albumin-based PRINT particles and 2) this may be a promising 
system for delivery of RNA replicon-based vaccines.  
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 CHAPTER 1 
 
INTRODUCTION TO RNA REPLICON AS NUCLEIC ACID VACCINE AND 
PRINT AS A PLATFORM TECHNOLOGY FOR DRUG DELIVERY
 
1.1 RNA replicon: Nucleic Acid-Based Vaccine 
 
At the end of eighteenth century, Edward Jenner showed that inoculation 
with cowpox can protect against smallpox, the “speckle monster” which, at that 
time, was the cause of 400,000 deaths per year in Europe.1 This discovery has 
saved millions of lives and initiated vaccine development as one of the central 
topics in modern biomedical research. Vaccination is the way to prepare the 
immune system against potential attackers such as viruses and bacteria by 
giving it a “simulation of battle conditions” without exposing the vaccinated 
individual to real infections. Vaccines have been extremely useful in fighting a 
variety of viral and bacterial infectious diseases since its first discovery and the 
scientific advances in this field during the last two centuries have significantly 
contributed to increased human life expectancy.  
1.1.1 Evolution of vaccines 
 
1.1.1.1 Attenuated pathogens for vaccines 
 
The initial effort for vaccine development is based on attenuated (live) or, 
inactivated (killed) pathogens. It was found that by growing pathogens in a cell 
type that is not its normal host, the pathogen would become weakened or 
2 
attenuated and this strategy results in pathogens that are still infectious but too 
weak to cause diseases. The vaccines currently used to protect against many 
diseases such as measles, mumps and rubella are in the form of attenuated 
pathogens.2 Attenuated vaccines are very effective to trigger both humoral and 
cell-mediated immune responses due to the ability of the weakened pathogens to 
infect antigen presenting cells (APC) and stimulate the production of cytotoxic 
lymphocytes (CTLs) and memory killer T cells before the immune system 
eliminates the weakened potential attacker. The CTL memory will protect the 
vaccinated individual from future attacks against the real infections, in most 
cases, for a long time.  
Although very efficient, however, attenuated pathogens as vaccines are 
inevitably accompanied by safety concerns. One safety concern is that the 
vaccinated individual may generate enough pathogens and spread it to people 
with weakened immune systems and cause harmful consequences. In addition, 
the attenuated pathogens may revert to their infectious forms and cause 
diseases in the vaccinated individual.  
1.1.1.2 Killed pathogens for vaccines 
 
Under these concerns, the vaccines based on killed pathogens which are 
inactivated through chemical, heat or radioactivity treatment have the advantages 
of being much safer than live, attenuated vaccines.3 Since the vaccines in the 
form of inactivated viruses or bacteria bear the full spectrum of antigens of 
pathogens, they may effectively trigger the generation of memory helper T and B 
cells which will provide sufficient protection against the attack from many 
3 
pathogens. For example, vaccines against Salk polio and Japanese Encephalitis 
viruses in the inactivated pathogen forms are in wide use.  In addition, in the 
case of influenza vaccines, the killed pathogens are easier to prepare in a time 
efficient way and are more widely used than live attenuated vaccines. For 
example, during the avian flu epidemic in 2005 and H1N1 epidemic in 2009, 
when there was a need to prepare vaccines in a short time for worldwide use, the 
inactivated vaccine was chosen as the best alternative.4 However, the killed 
pathogens are less effective in triggering immune responses compared to their 
attenuated counterparts because they are not capable of replicating in the host 
and are thus quickly cleared from the body without stimulating production of 
CTLs. It is believed by many immunologists that to be effective, vaccines against 
many diseases must generate CTLs and memory killer T cells.5 
1.1.1.3 Subunit vaccines 
 
Vaccines have also been prepared by using only certain parts of a 
pathogen or isolated viral proteins. The idea is to retain the parts for the immune 
system needs to see to adopt protection against the real infections. And in the 
case of bacterial, the disease-causing toxins secreted by some bacteria have 
been used for generating effective vaccines. For subunit vaccines, there is no 
possibility of causing infection with the pathogen itself and safety is an apparent 
advantage. In addition, recent advances in genetic engineering can produce 
proteins used as antigens in large quantities and in pure forms and have opened 
up new opportunities for subunit vaccine development. However, there are a 
number of drawbacks, including low efficacy and short-term immunity because 
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the injected protein is quickly consumed in the immunogenic process and does 
not activate immune responses in a broad and robust manner.  Frequently, an 
adjuvant is formulated together with the protein to increase the immune response 
by releasing the antigen over a longer period of time or eliciting inflammation that 
enhances antigen uptake and presentation by APCs. There have been many 
efforts to further improve the immune responses of the vaccines in the subunit 
forms by developing micro or nano particles for antigen delivery.  The hypothesis 
behind is that APCs have evolved to effectively take up and process antigens 
bearing similar dimensions to pathogens, ranging from sub- 100 nm to microns.6,7 
So antigens in particulate forms have the potential to achieve enhanced uptake, 
processing and presentation by APCs. 
1.1.1.4 Nucleic acid-based vaccination 
 
A main challenge for vaccine development is to design and produce 
vaccines that are safe but also induce long-lasting and robust immune responses 
in both humoral and cellular branches. About two decades ago, immunologists 
found that injection of naked DNA containing a flu virus gene into muscles of 
mice, without any associated lipid, protein or carbohydrate, elicited production of 
memory killer T cells against an influenza infection.8,9 The unexpected success 
was attributed to the gene being taken up by APCs which then generated the flu 
protein,  processed the protein and activated CTLs. This result has initiated a 
whole new scientific field and has been regarded as one of the most important 
discoveries in the history of vaccinology by some scientists.  
5 
Nucleic acids offer a unique opportunity for vaccination and have emerged 
as excellent candidates for the treatment of cancers and infectious diseases.10 
Compared with traditional protein-based vaccination strategy, direct 
immunization with RNA or DNA has the advantages of the simplicity and purity 
with which they can be produced, as well as coding for only protein(s) of interest 
(i.e. an antigen) at high levels in a reproducible manner, potentially triggering 
strong immune response by producing CTLs and memory killer T cells.  And 
because such vaccines only include part of the pathogen’s total genes, this 
method will not cause real infections. The advancements in genetic engineering 
and molecular virology have made it possible to create genes that would not 
otherwise be found in biological organisms and the gene sequences can be 
added or subtracted to improve the immunogenicity of an antigen. To date, 
several DNA vaccine products have been approved by FDA in the area of 
veterinary medicine.  
However, nucleic acid-based vaccines in the form of messenger RNA or 
plasmid DNA tested to date have had limited efficacy in humans, largely due to 
their inability to produce high dosages of antigen and for the duration required to 
trigger strong, durable immune responses. 11,12 To resolve the low efficacy issues 
of nucleic acid vaccines is currently the focus of many research groups and the 
potential resolution includes use of novel formulations, immune plasmid 
adjuvants and delivery systems to enhance immunogenicity etc.13 The use of 
replicative RNA is one of the strategies under investigation.12  
1.1.2 RNA replicon for vaccine applications 
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1.1.2.1 Introduction to RNA replicons 
 
RNA replicon, also termed self-replicating RNA, is an important form of 
nucleic acid-based vaccines and is derived from either positive- or negative-
strand RNA viruses such as Semliki Forest virus and Kunjin virus.14 The RNA 
replicons can be produced in large quantities by in vitro transcription and capping 
using a variety of DNA templates. From these viruses, the gene sequences 
encoding structural proteins are replaced by mRNA encoding antigens of interest 
as well as the RNA polymerase for RNA replicon replication and transcription. 
RNA replicons can be regarded as “disabled” virus vectors that are capable of 
amplifying within the cytoplasm of host cells for a prolonged period but are 
unable to produce infectious progeny. Cells transfected with conventional RNA 
vaccines express widely varying amounts of antigen, due to the number of gene 
copies picked up by the cell. RNA replicon has the advantage of being able to 
generate large quantities of antigens with a single piece of the gene being 
introduced into the cell.  Compared with DNA vaccines, which is also under 
active investigation, RNA replicon has several advantages: Firstly, RNA replicon 
is capable of replicating in the cytoplasm of host cells, thus avoiding the 
requirement of nucleus entry which represents a daunting hurdle in DNA 
delivery.15 By eliminating the dependence on cellular transcription machinery and 
transport of nucleic acids to and from the nucleus, RNA replicon is potentially a 
more efficient form of nucleic acid vaccine.16 Secondly, RNA replicon has 
superior biosafety features, which is crucial for vaccine purposes. Compared with 
DNA, RNA replicon can avoid the potential integration into the genome of host 
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cells and also prevent generation of anti-DNA antibodies, both of which may 
affect the host cell’s gene expression in an uncontrollable manner and thus 
represent incalculable risks.17 Also, RNA is self-adjuvanting. Diebold S. S. 
reported that single-stranded RNAs including both mouse mRNA and a wide 
range of synthetic RNAs can innate immune responses through TLR7-mediated 
recognition.18 RNA replicon combines the safety characteristics of inactivated 
vaccines with the superior immunogenicity of live, attenuated vaccines and has 
the potential to trigger effective immune responses against a variety of diseases. 
1.1.2.2 Initiation of immune response development  
 
An immune response is primarily launched by dendritic cells (DCs), a 
specialized bone marrow (BM)-derived APC. DC as the most important APC can 
potentially capture antigens generated by RNA replicon through three routes:19 
Firstly, DC can capture soluble antigens secreted or released by transfected host 
cells. Secondly, DC can be directly infected with RNA replicons and immune 
response will be induced when the antigens encoded are endogenously 
processed by mature DCs.  Thirdly, DC can take up the cells that have been 
killed or injured due to transfection of RNA replicons. The third route has been 
the focus of research investigation on the immunogenicity of RNA replicons.  
RNA replicon vaccines can employ the host cells’ machinery to replicate 
and encode desired antigens. Most research investigating initiation of immune 
responses by replicon vaccines has focused on two virus families: 1) 
alphaviruses, such as Semliki Forest virus and Sindbis virus; and 2) flaviviruses, 
such as Kunjin viruses and Yellow Fever viruses.20 There is a major distinction in 
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their cytopathic nature between RNA replicons derived from these two families of 
viruses. Alphavirus-derived replicons are generally cytopathic and the “self-
replicating” activity of these replicons can induce caspase-dependent apoptosis 
of transfected cells.21 Flavivirus-derived replicons are generally non-cytopathic 
and the RNA replicon can maintain in high copy numbers in the cytoplasm of 
transfected cells without interfering with normal cellular functions.22 In one 
regard, the non-cytopathic RNA replicons have the advantage of being able to 
produce antigens for prolonged periods of time, a feature that has been proved to 
be important in inducing effective immune responses. At the same time, cell 
damage or death triggered by replication of cytopathic RNA replicons can 
function as “danger signals” and effectively activate DCs and facilitate uptake of 
injured or killed cells by DCs, potentially enhancing immunogenicity.19 
Comparison of these two types of RNA replicon have been conducted and the 
influence of cytopathicity on the immunogenicity still remains controversial. Two 
groups used the anti-apoptotic molecule Bcl-XL in alphavirus replicon plasmid 
vaccines to delay the apoptosis of transfected cells and compared the 
immunogenicity with and without Bcl-XL. In one study, the immunogenicity of the 
plasmid vaccine was improved by prolonged survival of transfected cells,23 while 
in another study the efficacy of alphaviral replicase-based vaccine was reduced 
by Bcl-XL.24 Racanelli V. et al. compared the immunity stimulated by DCs 
transfected with cytopathic and non-cytopathic RNA replicons and found that 
induction of cell death increased the DC-associated antigen.22 Tannis L. L. et al. 
compared the cellular and humoral immunities elicited by RNA replicon based on 
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Semliki Forest virus (cytopathic) vs. Kunjin virus (non-cytopathic) RNA replicons 
and found that the two replicon systems elicited similar cellular responses while 
Semliki Forest virus elicited greater humoral responses.20 Currently it still 
remains to be determined which RNA replicon system has more advantages for 
vaccine purposes and this may be an important factor to consider when 
designing RNA replicon-based vaccines.   
1.1.3 Current approaches to administer RNA replicon 
 
The initial effort to use RNA replicon for vaccination is based on their 
naked forms and in vivo immunity has been achieved in mice through direct 
intramuscular injection.25 However, there are several drawbacks associated with 
this approach including the general liability of single strand RNA replicons and 
relatively low delivery efficiency without the protein coatings that protect the viral 
genome from degradation and facilitate entry into the host cell.   
One solution is to administer RNA replicon in a DNA-layered form.14 This 
approach resembles conventional DNA vaccines, but this DNA is transcribed in 
the nucleus into RNA replicon which is then exported from the nucleus and 
translated into polyproteins leading to the synthesis of RNA replicase and 
replication of RNA replicon. The DNA-layered form of RNA replicon can achieve 
high antigen expression due to the RNA replication but similar to conventional 
DNA vaccines, this process requires nucleus entry and is accompanied by a 
series of safety concerns such as the potential integration into the genome of 
host cells.  
Another solution is 
(VRP).14, 26 A helper RNA encoding structural proteins is introduced into cells 
along with the RNA replicon encoding the antigen (Figure 1.1). The replicase 
generated by antigen RNA rep
RNA and helper RNA. The structural proteins expressed by the helper RNA can 
package the antigen RNA (not the helper RNA) into VRPs which are then 
released from the cell. The practical utility of this appr
cost-effectiveness and large
production has to be monitored to avoid RNA recombination and generation of 
propagation-competent RNA genomes which may cause adverse health 
effects.27 A broadly applicable, scalable and cell
for RNA replicon has t
development.  
      
Figure 1.1 Generation of viral replicon particles (VRP). 
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to wrap the RNA replicon with viral replicon particles 
licon catalyzes the replication of both the antigen 
oach, however, is limited by 
-scale manufacturing considerations. In addition, the 
-free vaccine fabrication platform 
he opportunity to fundamentally transform vaccine 
 
The replicon RNA 
11 
encodes for the foreign antigen (green) and the viral non-structural proteins 
nsP1- nsP4 that form the active viral replicase. Upon introduction of RNA 
replicon into the cell, RNA polymerase is generated and catalyzes the replication 
of both replicon and helper RNA as well as transcription from the subgenomic 
promoters (Psg). The helper RNA encodes for the three main structural proteins 
C, E2, and E1 and two minor proteins E3 and 6K. After viral structural proteins 
are expressed, the replicon RNA (but not the helper RNA) is packaged into VRPs 
which are released from the cell. UT, untranslated region. ψSIN, ψSFV, packaging 
signals of Sindbis virus and SFV, respectively. Adapted from [14]. 
 
1.2 PRINT: A Platform Technology for Drug Delivery 
 
1.2.1 What is drug delivery 
 
Conventionally, drugs are administered in forms of pills, eye drops, 
ointments, and solutions injected intramuscularly, subcutaneously, intranasally or 
intravenously.28 Over the past few decades, there is a growing effort to address 
the problems associated with conventional forms of drugs such as low efficacy or 
harmful side effects with drug delivery systems. One approach is to take existing 
drugs and improve their biodistribution (BD, where the drug travels in the body) 
and pharmacokinetics (PK, the fate of the drug in the body), the major factors 
that directly affect the efficacy of the drug treatment.29 One example that belongs 
to this category is chemotherapies which reach all tissues in the body and 
adversely affect healthy cells. This undesirable effect requires that patients be 
administered with the tolerable, lower-than-optimal amount of drugs, significantly 
reducing the effectiveness of the treatment. Another approach is to seek new 
therapeutics which are more effective in treating diseases or less harmful for the 
healthy tissues but rely more on drug delivery systems to be effective. This is 
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common for drugs with very poor solubility or biopharmaceuticals that may be 
unstable and degraded by the body such as RNA and peptides.  
For the aforementioned reasons, numerous drug delivery carriers have 
been designed in different forms such as colloidal particles, patches, sutures and 
dressings etc. The mostly studied colloidal particles, for example, have been 
developed based on different techniques such as polymer particles,30 
liposomes,31 micelles,32 layer-by-layer (LBL) capsules33 and dendrimers34.  The 
advantages of using particles as drug delivery system include: 1) cargos can be 
incorporated into the particles and be protected from degradation or passive 
release into non-targeted tissues during the transportation in the body, 2) 
particles sizes and surface characteristics of particles can be designed to 
achieve biodistribution and targeting to specific tissues of treatment, as well as 
cellular internalization for drugs delivered intracellularly, 3) the controlled release 
of drug can be modulated to achieve the best efficacy, 4) the system can be 
administered through various routes including oral, nasal, parenteral, etc. 
1.2.2 Introduction to PRINT 
 
PRINT (Particle Replication In Non-wetting Templates) is a platform 
technology that is an off-shoot of soft lithography that enables the molding of 
micro- and nano-particles having precisely controlled size, shape, chemical 
composition and surface functionality for broad applications in life sciences and 
material sciences.  
PRINT was first developed in DeSimone group at University of North 
Carolina in Chapel Hill in 2005.35 Silicon wafers patterned with different features 
are fabricated using standard photolithographic techniques and used as ma
in PRINT process. A photocurable perfulorinated polyether (PFPE) liquid polymer 
which has been trademarked Fluorocur
completely wet the silicon wafer with micro
extremely low surface energy and can subsequently be photocured to form PFPE 
elastomer mold (Figure 1.2). The PFPE
surface energy, high gas permeability, high solvent resistance, high elastic 
recovery and good mechanical strength. 
performance to poly(dimethyl siloxane) (PDMS), the most commonly used 
elastomer for the fabrication of microfluidic devices an
translate into a top-down approach of soft lithography that offers an engineering 
way to produce isolated micro
manufactured on roll-to-roll machines and provided by Liquidia Technologies in
1000 ft rolls.  
Figure 1.2 The PRINT mold fabrication. (A) Fluorocur (green) is poured onto a 
silicon wafer template (grey), (B) The Fluorocur completely wets the surface of 
the template and is then photochemically cured, (C) The mold is removed from 
the template and shows the inversed features of the template. 
 
A typical PRINT process is schematically illustrated in Figure 1.3. 
Following generation of a PFPE mold (green) from the master template (grey), a 
liquid substance (red) is filled into the cavit
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® by Liquidia Technologies
- and nano-sized patterns due to its 
-based PRINT mold has extremely low 
This material demonstrated superior 
d its unique properties 
- and nano-particles.  The mold can now be 
 
ies with assistance from a piece of 
sters 
 can 
 
 
high energy polyethylene terephthatlate (PET) and a roller applying pressure to 
the mold. The low surface energy of the PRINT mold enables the liquid to fill the 
cavities through capillary filling, but without wetting th
cavities and the excess liquid substance will adhere to the high energy PET. In 
this step, if a PDMS mold which has higher surface energy than PFPE, a flash 
layer of the liquid connecting the cavities which is termed “scum layer”
formed and no isolated particles can be generated.
mold cavities is converted to a solid through photocuring, temperature change, 
solvent evaporation, etc., the array of particles (red) can be removed from
mold by bringing the mold in contact with an adhesive layer (yellow). The 
particles can now be easily freed from the surface by mechanical force or 
dissolving the adhesive layer. 
Figure 1.3 The PRINT particle fabrication process.
1.2.3 Control over all aspects of particle fabrication
 
1.2.3.1 Control over size and shape
 
To date, precise template fabrication has been achieved in electronics 
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e landing area between the 
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 Once the liquid in the PFPE 
 
 
 
 
 will be 
 the 
 
industry due to the advancements in standard lithography and the PRINT 
process takes full advantage this state of the art technology to make uniform 
particles of unlimited sizes and sha
identical template features to afford particles that are truly monodisperse.  PRINT 
allows for the precise control over particles size down to sub ~100 nm and 
PRINT mold with a 50 nm 
Liquidia Technologies. Shape features can be controlled through the choice of a 
template and geometries of particles such as spheres, cylinders, discs and 
toroids with different aspect ratios can be precisely defined. Figure 1.4 shows a 
selection of particles which have been fabricated using the PRINT process.
Figure 1.4 A variety of sizes and shapes generated using PRINT technology. 
Scale bars in (A), (B) and (C) represent 1 
represent 5 µm.  
 
Particle sizes and shapes could affect cellular internalization,
aerodynamics,38, 39 circulation and biodistribution in the body
profiles41.  PRINT can be used as an effective tool to study the role of size and 
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pes. The PRINT ensures replication of 
× 60 nm cylindrical feature can now be obtained from 
µm and scale bars in (D), (E) and (F) 
40
  and drug release 
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shape of the particles on all the biological processes mentioned above. Cellular 
internalization of PRINT particles has been studied by Gratton S.E. et al. and it 
was found that cell uptake exhibited a strong dependence on particle size and 
shape.42 Interestingly, the internalization of the rod-like, high aspect ratio 
nanoparticles occurs much more rapidly and efficiently than would be expected 
based on size considerations alone, indicating a special role associated with the 
shape of the particles. 
1.2.3.2 Control over composition  
 
In addition to control over size and shape, the composition of particles 
fabricated from PRINT process is also readily tunable. The PRINT particles can 
now be fabricated from a variety of compositions (Figure 1.5): 1) Hydrogels such 
as cross-linked poly(ethylene glycol)s (PEG) and poly(silyl ether)s. PEG is a 
biocompatible polyether-based material and has wide applications in medicine 
and in the drug delivery field.43 Parrot M. C. et al. developed a tunable silyl ether 
based acid-sensitive biomaterial and mold the material into medical devices 
including PRINT particles, sutures and stents.44 These devices can preferentially 
degrade and release the model drug under acidic conditions known to exist in 
tumor tissue, inflammatory tissue, and diseased cells. 2) Polymers such as 
poly(lactic acid) (PLLA) and poly( lactic-co-glycolic acid) (PLGA).45 PLLA and 
PLGA are both biocompatible, bioabsorbable materials and have shown great 
promise in medical applications. 3) Biologics such as insulin and albumin, etc.46 
Biologics such as protein and polypeptides have been extensively studied both 
as integral components an
drug delivery systems.  
 
Figure 1.5 PRINT particles generated f
Poly(ethylene glycol) 2 µm × 2 
PLGA, 1µm × 1µm cylinder
µm × 1 µm hexnuts, scale bar represents 10 
scale bar represents 5 µm
 
The unprecedented control over particle composition makes PRINT a 
platform technology in 
hydrophobic therapeutic molecules, biologicals, peptides, proteins, contrast 
agents, radiotracers et al. can be accommodated through inclusion in the particle 
matrices of choice.  In addition, the porosity,
can be altered through careful design of matrices formulation for different 
applications. For example, Merkel T. J. et al. reported that the modulus of 
microparticles could be decreased by decreasing the cross
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d as effective therapeutics in the development of novel 
rom different compositions. (A) 
µm × 1 µm cubes, scale bar represents 5 
s, scale bar represents 10 µm, (C) poly(silyl ether), 3 
µm, (D) insulin, 2 µm × 4 
.  
that a variety of cargos including hydrophilic or 
 texture and modulus of the particles 
-linking density of the 
 
µm, (B) 
µm cubes, 
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hydrogel matrices, resulting in increasingly longer circulation times for these 
particles.47 These long-circulating particles can potentially be used to generate 
mimic red blood cells. Interestingly, multiphasic and regio-specifically 
functionalized particles can also be fabricated using PRINT. Zhang H. et al. 
developed a strategy to prepare end-labeled particles, biphasic Janus particles 
and multiphasic shape-specific particles by integrating two compositionally 
different chemistries into a single particle.48 
1.2.3.3 Control over surface properties 
 
The surface properties of the PRINT particles including charges and 
functional groups can also be modulated. One approach is to accommodate 
molecules with chemistry reaction handles in the PRINT particles and then post-
functionalization through chemical reactions after PRINT process can be used to 
effectively tailor the surface properties. For example, Gratton S. E. et al. treated 
surface amine groups on the PEG-based particles with acetic anhydride, 
converting the zeta potential of nanoparticles from positive to negative.42 The 
results indicated that positively charged nanoparticles were readily internalized 
whereas the identically shaped negatively charged particles showed minimal cell 
internalization. Wang J. et al. developed strategies to modify the surface 
functional groups of the PEG-based PRINT nanoparticles through conjugation 
with human transferring or transferring receptor monoclonal antibody (Figure 
1.6).49 The 200 nm × 200 nm cylindrical PRINT nanoparticles labeled with 
transferrin receptor antibody or human transferrin showed highly specific 
Transferin-mediated uptake by all human tumor cell lines tested, while negative 
controls (IgG1 and bovine transferring) showed minimal internalization. Another 
approach is to modify the surface properties o
physical absorption. Hasan W. et al. developed a PLGA
siRNA. The lipids were absorbed onto the surface of the PLGA nanoparticles 
through hydrophobic-hydrophobic interaction (Figure 1.7) and facilitated 
uptake as well as endosomal escape of the particles.
control over surface properties which greatly affect cell internalization 
biodistribution of particles and is a platform for target
        
Figure 1.6 Post-functionalizations of PRINT nanoparticles. Top: with 
human/bovine transferrin through lysine
transferrin receptor monoclonal antibody OKT9 and its isotype control IgG1
through biotin-avidin strategies.
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ed drug delivery.
-maleimide reactions, bottom: with 
 Adapted from [41]. 
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and 
 
  
 
                       
Figure 1.7 TEM image of lipid coated PRINT PLGA
Adapted from [49]. 
 
1.2.4 PRINT particles for delivery of therapeutics
 
In addition to the fact that PRINT is compat
chemistry composition and the gentle nature the particles can be fabricated, this 
technology also has the advantage of a straightforward incorporation of a variety 
of cargos. Based on the nature of the cargo, the appropriate parti
be selected and the cargo encapsulation can be achieved through mixing the two 
components and any other additives, if there is any, to form a pre
material, followed by filling the cavities with the pre
1.2.4.1 PRINT particles for delivery of chemotherapeutics
 
Enlow E. M. et al. reported the delivery of a chemotherapeutic drug, 
docetaxel, with PLGA PRINT nanoparticles.
drug and has very limited solubility in
mixed in an organic solvent mixture (DMF:DMSO=4:1) and the one
particle material can be molded into nanoparticles using PRINT technology. 
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-siRNA nanoparticles. 
 
ible with a wide range of 
cle matrices can 
-particle material.  
 
45
 Docetaxel is a highly hydrophobic 
 water. PLGA and docetaxel can be evenly 
-particle 
-phase pre-
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Compared with other methods to fabricate PLGA-docetaxel particles, PRINT 
enjoys exceptionally high loadings of the drug in the particles up to 40% (w/w) 
with encapsulation efficiencies > 90%. In addition, the particles with different drug 
loadings possessed exactly the same particle size and shape and were 
fabricated without the necessity of adjustments to the process. The PLGA 
particles without drug showed minimal toxicity on the cell lines investigated and 
drug-loaded particles showed high toxicity in vitro.  The commercially available 
formulation of docetaxel, Taxotere, was outperformed by the 30% and 40% 
drug loading PLGA-docetaxel PRINT particles in toxicity.  The in vivo efficacy of 
the PLGA-docetaxel particles bearing different sizes and shapes is currently 
being investigated.  
1.2.4.2 PRINT particles for gene delivery 
 
The PLGA particles were also investigated as delivery vehicles for siRNA. 
Hasan W. et al. developed a simple two-component PLGA-siRNA nano-particle 
system which allows for protection of siRNA from degradation as well as 
controlled release of the cargo.50 Similar to the loading of docetaxel, siRNA and 
PLGA were mixed evenly to form pre-particle material which was then filled into 
the cavities of PRINT mold. Lipids were coated on the surface of the particles at 
the time of particle harvesting to facilitate cell uptake as well as particle 
transfection. The internalization of the lipid-coated PLGA/siRNA nanoparticles 
was achieved on multiple cancer cell lines and the particles have successfully 
shown in vitro knockdown of therapeutic genes relevant to prostate cancer. The 
in vivo efficacy of lipid/PLGA/siRNA nanoparticle system is currently under 
22 
investigation.       
1.3 Summary 
 
In summary, RNA replicon is highly effective for generating cellular and 
protective immune responses and has shown great promise to treat and protect 
against a variety of diseases, but it is essential to find a method to effectively 
deliver the RNA replicon molecule.  PRINT technique developed in our lab is a 
platform that allows for the precise and simultaneous control over all the 
parameters that are essential to protect and deliver the delicate biological cargos. 
PRINT is also amenable to continuous roll-to-roll fabrication techniques that 
enable the scale-up of the particle fabrication under good manufacturing practice 
(GMP) compliance. PRINT has the straightforward incorporation of a variety of 
cargos which can be accommodated through inclusion in the particle matrices in 
a “plug-and-play” manner. This broadly applicable and readily tunable platform 
has the potential to fundamentally revolutionize vaccine development. The goal 
of the research here is to develop a particle system based on PRINT to 
effectively deliver RNA replicon in vitro and in vivo and ultimately initiate effective 
protection against diseases.  
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 CHAPTER 2 
 
NOVEL DISULFIDE-BASED CROSS-LINKER RENDERING PROTEIN-BASED 
PARTICLES TRANSIENTLY INSOLUBLE FOR THERAPEUTIC 
APPLICATIONS 
 
2.1 Introduction 
 
Delivering promising biological therapeutics like RNA replicons to the 
desired location in the body in a safe and effective fashion is one of the key 
challenges in medicine. A protein matrix was chosen for the delivery of RNA 
replicons based on the fact that both RNA replicon and protein are highly 
hydrophilic and dissolve readily in aqueous solutions in which RNA replicons and 
proteins can be evenly mixed together and subsequently molded into particles 
utilizing PRINT technology. 
Drug carriers using proteins as matrices for the delivery of small molecule 
drugs and biological cargos, such as plasmid DNA and siRNA, are being 
extensively studied. In addition, protein-based therapies, which involve the 
delivery of therapeutic proteins or polypeptides, such as tumor necrosis factor, 
and monoclonal antibodies, are considered a safe and effective approach to treat 
many diseases. Each of these applications would benefit from having protein-
based particles that dissolve slowly in a controlled and desirable manner. 
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2.2 Protein-based Particles for Drug Delivery and Conventional 
Fabrication Methods 
 
2.2.1 Protein-based particles for drug delivery 
 
Proteins as the matrices for drug delivery particles have many advantages 
including biodegradability, biocompatibility and amenability to surface 
modification.1 There are over 30 therapeutics compounds that have been 
investigated with protein-based drug delivery systems including chemotherapies, 
e.g., doxorubicin, docetaxel, paclitaxel, and gemcitabine, and biopharmaceuticals 
such as plasmid DNA, siRNA, etc. 2 The proteins under active investigation 
nowadays include gelatin 3, albumin 4, collagen 5, gliadin etc. Table 2.1 shows a 
list of proteins that have been used to prepare drug delivery systems, their 
properties and examples of the therapeutics that have been delivered by these 
systems.  
 
Table 2.1 List of proteins investigated as matrices for drug delivery systems, 
partially adapted from [2].  
Protein Properties 
 
Drugs investigated 
 
Albumin 
1. Mw of 66.5 kDa, highly soluble in water, 
moderately soluble in concentrated salt 
solutions 
2. Iso-electric point  (pI) is 4.75, slightly 
negative charged in physiological condition 
3. Robust to various conditions  
Doxorubicin, 
paclitaxel, plasmid 
DNA6, siRNA7 
Collagen 
1. Has a three dimensional helical structure 
and is neutral-salt soluble or acid soluble 
2. Poor mechanical strength 
3. Contains carboxyl groups and secondary 
amino groups with possible cross-linking 
function 
Glucocorticosteroids, 
all-trans retinol 
Gelatin 1. Hydrolyzed form of collagen, possesses a 
random coil structure and many carboxyl 
Colchicine, 
thrombocidin (rTC-
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groups, soluble in water at above 35-40°C, 
gels below 35-40°C 
2. Type A pI 7.0-9.0, type B pI 4.8-5.0 
3. Widely used as an capsule ingredient in 
drug formulations 
1), lysozyme 
Gliadin 
1. Protein of vegetarian source 
2. Highly soluble in water and slightly 
soluble in ethanol 
3. Can fuse with sensitive enzymes and 
protect them from breaking down in contact 
with stomach acids 
Superoxide 
dismutase 
Silk-
elastin-like 
polypeptide 
1. Processes a pentapeptide repeatable unit 
as Val-Pro-Gly-Xaa-Gly 
2. Structure and properties can be 
engineered  
Insulin8, doxorubicin, 
plasmid DNA 
Ferritin/ 
apoferritin 
1. A globular protein complex consisting of 
24 protein subunits, has a Mw of 450 kDa 
2. Stores and releases iron in a controlled 
fashion 
3. Found intracellularly in all cell types 
RGD4C peptide 
Whey 
protein 
1. A mixture of globular proteins and soluble 
in water, independent of pH 
2. Widely used in food products because of 
their high nutritional value and their ability to 
form gels, emulsions, or foams 
riboflavin, caffeine, 
retinol 
 
Viral 
capsid 
1. Protects the nucleic acid of a virus 
2. Composed of capsomers, the individual 
morphological units 
3. Can form Virus-like particles through self-
assembly with RNA molecules 
Protein, RNA 
eplicon9 
Zein 
1. Used to deliver hydrophobic drugs  
2. Has antibacterial activity,  
3. Protects ivermecin from photodegradation  
4. Cost-effectiveness 
Ivermectin 
Heat shock 
proteins  
1. Involved in the folding and unfolding of 
other proteins when cells are under the 
stress of high temperature, etc. 
2. Uniform cage sizes with 12 nm exterior 
and 6.5 nm interior   
3. Large pores (3 nm) between interior and 
exterior for easy cargo exchange  
4. Used as scaffold for chemical reactions 
and material synthesis 
RGD 4C peptide, 
anti-CD4 antibody, 
doxorubicin 
Casein 1. Consists of proline peptides and no disulfide bridges 
Progesterone, 
doxorubicin, 
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2. Used to incorporate hydrophobic drugs 
3. Robust under various conditions  
theophylline 
 
 
2.2.2 Conventional methods to prepare protein-based particles 
 
Conventionally, the micro- and nano-sized protein particles are often 
made through processes which include solvent evaporation, micro-emulsion, 
spray-freeze-drying methods etc. Much effort has been dedicated to investigating 
the effects of numerous protein processing parameters such as temperature, 
humidity, composition, and fabrication method in order to retain the protein’s 
native state and biological function.  
Protein particles can be prepared through a solvent evaporation 
(desolvation) technique.10 Typically, the aqueous solution of protein is added to 
an excess of the stabilizing solvent (e.g. ethanol) wherein the aqueous phase is 
subjected to evaporation and protein particles grow in size as the reaction 
continues.  
Micro-emulsion is another important fabrication method used for protein 
particles, which involves the use of a dispersing oil phase.11 In the process, the 
aqueous protein solution is dispersed in an immiscible liquid (oil phase, e.g. 
cottonseed oil) and the mixture is then shaken and sonicated vigorously to create 
an emulsion. The emulsion formation step determines the size and size 
distribution the resulting micro-particles. The dispersed droplets of protein 
solution are usually further stabilized by heat or chemical cross-linking to form 
hardened protein particles.  
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In the process of spray-freeze-drying, a liquid feed containing dissolved 
protein is first broken into tiny droplets by an ultrasonic atomizer and the resulting 
droplets are frozen in contact with cold gas (or cryogenic liquid).12 Solid protein 
particles are obtained after the frozen droplets solidify at low temperature and 
pressure. The stress imposed on proteins in the atomization step and the 
extremely rapid freezing of droplets differentiates spray-freeze-drying from 
lyophilization which is normally used to prepare protein powders.  
Other protein particle fabrication methods include a supercritical fluid 
method13, the isoelectric point precipitation method (pH-coacercation)14 and 
templating mesoporous silica spheres15 etc. Frequently, these procedures result 
in highly heterogeneous spherical or granular particles and don’t allow for control 
over particle size or shape, resulting in particle populations of significant 
heterogeneity. Moreover, many of these processes are not compatible with 
optimal production of biological particles, as denaturation and aggregation of 
proteins tend to occur during processing. Another disadvantage associated with 
these methods is the costly and complicated processes which limit their ability to 
manufacture in bulk quantities. 
2.3 Fabrication of Protein Particles Using PRINT Technology 
 
2.3.1 Introduction 
 
Fabrication of PRINT protein particles has been achieved by a solvent 
evaporation strategy. 16 PRINT protein particles were prepared by filling 25 wt% 
protein solution in water into the PRINT mold and removing excess solution 
through multiple delamination steps. Then the filled mold containing aqueous 
protein solution was frozen and lyophilized overnight to remove the water. 
Particles were harvested using medical adhesive layer 
Providone (poly(vinyl pyrrolidinone)). Figure 2.1 shows the SEM images of the 
PRINT protein particles. Fluorescent dye was introduced into the particles and 
dissolution of the particles was mon
indicated that molding process did not change the dissolution characteristics of 
the protein particles (Figure 2.2). 
 
Figure 2.1 SEM images of PRINT protein particles. Left: 200 nm Abraxane 
particles harvested on med
siRNA particles harvested on medical adhesive layer, right: harvested and 
dispersed 200 nm albumin particles.
 
 
Figure 2.2 Fluorescent images of 5 
Povidone (left) after adding
dissolution (right). 
 
There are several disadvantages associated with this method that limit the 
particle fabrication efficiency especially in bulk quantities. Firstly, the filling 
process requires multiple delaminating steps to remove the excess protein 
solution that may form a scum layer connecting the particles together. Secondly, 
the lyophilization step is time
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poly(cyano acrylate
itored using microscope. The results 
 
ical adhesive layer, middle: 200 nm albumin with 
 
µm albumin particles with dye harvested onto 
 water to watch dissolution (middle) and after full 
-consuming and requires demanding instrument 
) or 
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setups. Thirdly, the particle harvesting with adhesive only allows for particles to 
be harvest on centimeter-square scales.  Having found the limitations of the 
solvent evaporation PRINT method, a new method was sought with the ability to 
fabricate PRINT protein particles on a scale that is practical for therapeutic 
application studies. Scientists at Liquidia Technologies developed a protein 
particle fabrication method based on the previous success in the fabrication of 
protein particles and poly (lactic-co-glycolic acid) particles. In this method, 
diluents or plasticizers based on lactose and glycerol can be mixed with the 
protein of choice to form the pre-particle material that “flows” when heated. 
Herein, the strategy is further optimized to increase gentleness toward protein 
and other biologic cargos. Serum albumin was chosen in this study for two 
reasons.  As the most abundant blood plasma protein it is essential for the 
transport of many physiological molecules and it also has the advantage of being 
readily available. Abraxane®, an albumin based paclitaxel containing 
nanomedicine, has achieved tremendous success as an approved treatment for 
metastatic breast cancer.17 In particular, bovine serum albumin (BSA) was used 
in this study due to its easy accessibility, cost effectiveness and availability in 
RNAse-free grade for our proof-of-concept study. 
2.3.2 Fabrication of albumin particles using PRINT technology 
 
2.3.2.1 Materials 
 
Bovine serum albumin was from Calbiochem. BCA protein assay reagent 
was from Thermo Scientific. Alexa fluor 555® labeled Bovine serum albumin was 
purchased from invitrogen. Lactose assay kit was purchased from Abcam. α-D-
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Lactose, glycerol and anhydrous isopropanol were purchased from Acros. Pre-
fabricated molds with 200 nm × 200 nm (mold # MMM-369-070) and 1 µm × 1 µm 
(mold # MMM-262-090A, MMM-369-070) cylindrical features and poly(ethylene 
terephthalate) (PET) sheets coated with Plasdone films were obtained from 
Liquidia Technologies.  
2.3.2.2 PRINT albumin particle preparation 
 
The bovine serum albumin (BSA) PRINT particles (1µm × 1µm, cylindrical) 
were derived from a mixture composed of 37.5 wt % of BSA, 37.5 wt % of D-
lactose and 25 wt % of glycerol. A 7.8 wt% solution of this mixture in water was 
prepared and then cast a film onto a PET sheet with a #7 Mayer rod (R.D 
Specialties) (Figure 2.3 A). Water was removed with a heat gun moving back and 
forth.  The film was optically transparent and was laminated onto a piece of 
PRINT mold (1 × 1 inch, cylindrical, d =1µm, h = 1µm), forming a sandwich 
structure with the film in the middle (Figure 2.3 B and C). This laminating step 
was carried out under a humidity level of 30-35% (based on 11-661-8 humidity 
meter, purchased from Control Company, TX 77546).  The mold and the PET 
were passed through a heated laminator with a temperature of 60 °C on the 
heated roller and a pressure of 80 psi between the rollers and split (Figure 2.3 D 
and E). In this step, the PET and mold were passed through the heated laminator 
with the PET sheet facing the heated roller. The filled mold was relaminated onto 
a sheet of Plasdone covered PET (Figure 2.3 F and G). The laminated mold and 
PET were passed through the heated laminator again (Figure 2.3 H). After the 
filled mold cooled down (placed at room temperature for 1 minute), the mold and 
the PET were separated gently and all the PRINT particles were transf
the mold to the Plasdone film
the PET by dissolving Plasdone with isopropanol
particles were washed with isopropanol for three times by centrifugation to 
remove Plasdone.  
Figure 2.3 The fabrication process for protein
lactose and glycerol were dissolved in water to create a solution (r
mayer rod is then used to draw a film from this solution on a PET sheet. Water is 
removed and a solid film is generated.  (B) A PRINT mold (green) is laminated 
onto the film. (C) The mold with pre
a heated pressured nip (grey) and split. (E) The cavities of the mold are filled. (F) 
The filled mold is laminated onto a sacrificial adhesive layer (
PET sheet, yellow). (G) The mold with the sacrificial adhesive layer. (H) The mold 
is passed through the nip again without splitting. (I) After the mold cools down, 
the mold is peeled off and particles are transferred to the adhesive layer. (J) The 
sacrificial adhesive layer was dissolved to free the particles.
 
Particles with a 200 nm × 200 nm 
following the same procedures with adjusted parameters. The particles were 
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 (Figure 2.3 I). The particles were harvested from 
 (Figure 2.3 J). The harvested 
-based PRINT particles. BSA, 
-particle film. (D) The mold is passed through 
Plasd
 
cylindrical feature were fabricated 
erred from 
ed). (A) A 
one film on 
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derived from a pre-particle mixture composed of 54 wt% of BSA, 30 wt% of D-
lactose and 16 wt% of glycerol. A 5.0 wt% solution of this mixture in water was 
cast a film onto a PET sheet with a #5 Mayer rod (R.D Specialties). PRINT mold 
(1 × 1 inch, cylindrical, d =200 nm, h = 200 nm) was laminated onto the pre-
particle material film under a humidity level of 40-45%. The mold was filled by 
passing the mold and the PET through a heated laminator with a temperature of 
93 °C on the top roller and a pressure of 80 psi between the rollers. The particles 
were then transferred onto Plasdone film and harvested using isopropanol.  
2.3.2.3 Scanning electron microscopy (SEM) 
 
For visualization samples were coated with 2 nm gold palladium alloy 
using a Cressington 108 auto sputter coater. Images were taken at an 
accelerating voltage of 2 kV using a Hitachi model S-4700 scanning electron 
microscope (SEM).  
2.3.2.4 Particle composition analysis 
 
Particles were dispersed in water.  The amount of BSA was measured 
using HPLC (Agilent Technologies 1260) with a C18 rapid resolution column 
(Zorbax Eclipse plus, 4.6 × 100 mm, 3.5 micron).  A mobile phase of water and 
acetonitrile on a gradient from 85% of water to pure acetonitrile over 15 minutes 
with a flow rate of 0.6 mL/min was employed with a detection temperature of 50 
°C on the ELSD (Agilent Technologies 1260).  The BSA peak appeared at 8.2 
minutes and the peak area was compared to the BSA standard curve to 
determine the concentration of BSA in the particle solution.  The particle solution 
was filtered with centrifugal filters (Amicon ultra, 0.5 mL, MWCO 30K) to remove 
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BSA.  The filtered solution was analyzed using HPLC with a Hi-plex Ca column 
(Agilent, 300 × 7.7 mm, 8 micron). A mobile phase of pure water over 25 minutes 
with a flow rate of 0.6 mL/min was employed with a detection temperature of 26 
°C on the ELSD.  The lactose peak appeared at 9.3 minutes and the glycerol 
peak appeared at 16.3 minutes.  The concentrations of lactose and glycerol in 
the particle solution were calculated based on lactose and glycerol standard 
curves. 
2.3.2.5 Dissolution test in water 
 
The cylindrical particles (1µm × 1µm) were labeled with Alexa fluor 555® 
and the particle stability in water was visualized with fluorescence microscope. 
The particles were derived from a mixture composed of 37.0 wt% of BSA, 37.0 
wt% of lactose, 25.0 wt% of glycerol and 1.0 wt% of Alexa fluro 555® labeled 
BSA. The particles were transferred onto the sacrificial adhesive layer and 
visualized with fluorescence microscope before and after addition of water.  
2.3.3 Results and discussion  
 
This thermal fill method has the ability to fabricate protein particles on a 
large scale in a convenient and efficient way, a benefit over the solvent 
evaporation method. For example, fabrication of 1 mg of 1µm × 1µm cylindrical 
particles using the solvent evaporation method and particle purification take 
several hours of bench work and also requires an overnight lyophilization 
procedure. As a comparison, fabricating and purifying the same amount of 
particles takes approximately half an hour with the new method. Figure 2.4 
shows the successful fabrication of 1
cylindrical particles using the thermal fill method.
 
Figure 2.4 1µm × 1µm (A) and 200 nm × 200 nm (B) cylindrical BSA particles.
 
The thermal fill method is based on the heating pre
its Tg and reaching a state of flow. BSA in a lyophilized form can be significantly 
denatured even heated to an unsoftened state and can not fill the mold without 
addition of plasticizing agents. Lactose and glycerol are both regarded as GRAS 
materials (generally regarded as safe) by FDA and have been commonly used as 
plasticizers in food and pharmaceutical industries. Introducing these two 
components into the formulation significantly 
material and the temperature used to make this material flow can be as low as 60 
°C for 1µm × 1µm cylindrical particle fabrication, which avoids the obvious 
degradation of the protein and delicate biological therapeutics that we are looking 
at.  
There are two main 
formulation: 
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µm × 1µm (A) and 200 nm × 200 nm (B) 
 
-particle material above 
dropped the Tg of the pre
factors that affect the mold filling of a pre
 
 
-particle 
-particle 
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1) Contact angle of the pre-particle mixture on the PRINT mold. The filling 
of the PRINT mold happens when the capillary force pulls the pre-particle 
material into the nano-scale or micron-scale cavities.  At the same time, the pre-
particle material has to be non-wetting on the surface of the mold, preventing the 
generation of flash layers between the particles. The surface tension of the pre-
particle material and the contact angle on the patterned mold surface determine 
the “PRINT-ability” of certain formulations. This explains the fact that certain 
protein-lactose-glycerol formulations can fill the mold under a flow state but can 
not generate isolated particles.  Fabrication of 200 nm × 200 nm cylindrical using 
a pre-particle mixture of 40 wt% of BSA, 30 wt% of lactose and 30 wt% of 
glycerol under a humidity level of 40-45% resulted in some isolated particles and 
a significant amount of scum (Figure 2.5 A).  
2) Humidity level. In the process of pre-particle film preparation, most 
water is removed but certain amount of water still exists in the pre-particle 
material, reaching a state of equilibrium with the water in the air. Water is also 
widely used as a plasticizer for hydrophilic polymers and the amount of water in 
the pre-particle material strongly affects the property of the film. For example, 
Figure 2.5 (B) showed particles derived from the same formulation as for the 
particles shown in Figure 2.2 (B), but under a higher humidity (55%).  In this 
case, the particles appeared to be significantly interconnected with a flash layer. 
As a comparison, the same pre-particle material was filled under a humidity level 
of 20%, which generated very minimal mold filling. The result indicated that the 
humidity level in the air has to be strictly controlled so that particle fabrication ca
be reproducible using a particular formulation.
Figure 2.5 (A) 200 nm × 200 nm cylindrical particles derived from a mixture of 40 
wt% of BSA, 30 wt% of lactose and 30 wt% of glycerol under the humidity level of 
40-45%, (B) 200 nm × 200 nm cylindrical p
composed of 54 wt% of BSA, 30 wt% of D
the humidity level of 55%, (C) 200 nm × 200 nm cylindrical mold filled with a 
mixture composed of 54 wt% of BSA, 30 wt% of D
glycerol under the humidity level of 20%. 
 
Images were taken of the 1
Alexa Fluor 555 on the sacrificial adhesive layer before and aft
water (Figure 2.6).  The particles dissolved instantaneously 
water, which also illustrated that the molding process didn’t change the 
dissolution properties of albumin and indicated the necessity for a cross
stabilize the albumin particles transiently.
 
Figure 2.6 BSA particle dissoluti
Particles transferred on to Plasd
after 10 s, (C) Particles with water added after 5 min.
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2.4 Synthesis of Novel Disulfide-based Cross-linker   
 
2.4.1 Introduction 
 
Dry microspheres or nanospheres composed of proteins are usually 
instantaneously soluble when placed into aqueous solutions.  A couple of 
strategies have been reported that maintains the stability of protein-based 
particles: i) thermal cross-linking, which causes the formation of intermolecular 
disulfide bridges between free thiol groups;18  ii) the use of non-reversible 
chemical cross-linkers, such as 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC), glutaraldehyde, formaldehyde etc.; 11, 19 and iii) the use of reversible 
cross-linkers like Lomant's reagent, dithiobis[succinimidyl propionate] (DSP), 
which can be cleaved upon exposure to certain biologic conditions.  Thermal 
cross-linking involves the thermal denaturation of a given protein at high 
temperature and cannot be applied to the delivery of functional therapeutic 
proteins.  The use of non-reversible chemical cross-linkers introduces permanent 
cross-linkages between individual protein molecules which limit the release of 
free protein molecules.  Such an approach has limited utility for the delivery of 
therapeutic proteins and biological cargos.  Reversible cross-linkers can be 
cleaved upon exposure to certain biologic conditions but leaves a chemical 
residue ―a potential neo-epitope―on the protein after cleavage of the disulfide 
bond (Scheme 2.1 a).20, 21 If the released protein from the particles has molecular 
pendants attached, it may elicit undesirable immune responses towards foreign 
antigens, which may induce adverse health effects.  In addition, for therapeutic 
proteins, very often, lysine residues are also involved in the active sites and 
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modifying lysine residues with molecular pendants, if DSP is used, may abolish 
the protein activity. 
In order to utilize protein-based particles for therapeutic applications like 
RNA replicon delivery, they are usually stabilized with cross-linkers, which can be 
cleaved under certain physiological stimuli.22 The site of action for RNA replicon 
is cytoplasm of cells which is known for its high concentration of reduced 
glutathione (GSH) compared to the extracellular environment (GSH 
concentration differs by 1000 folds intracellularly and extracellularly).23  In this 
study, we take advantage of the reducing environment in the cytoplasm of cells 
by introducing a disulfide-based cross-linker that should trigger the intracellular 
dissolution of our protein particles and release of RNA replicon from the particles.  
Our initial studies using DSP to cross-link BSA particles indicated that di-N-
hydroxysuccinimide (NHS) ester is highly reactive towards lysine residues on 
BSA and it is very difficult to control the cross-linking density of BSA particles, 
which is essential to achieve desired dissolution profiles.  In addition, even 
though DSP is advertised as a reversible cross-linker, it is not a “truly” reversible 
cross-linker as it will leave molecular pendants after disulfide cleavage under 
reducing environment (Scheme 2.1a).  
All the aforementioned concerns motivated us to develop a truly reversible 
disulfide cross-linker with well-controlled reactivity.  Wender et al. developed a 
disulfide based pro-drug linker, which contains a carbonate group instead of 
conventionally used ester linkage, to release the drug in its original state.24, 25  
This chemistry has also been applied to develop a fluorogenic probe for thiol 
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detection and a pro-drug for intracellular delivery.26, 27, 28   Inspired by previous 
work, we substituted the ester moieties in DSP with carbonate groups and 
developed a novel cross-linker dithio-bis(ethyl 1 H-imidazole-1-carboxylate) (DIC) 
for this study (Scheme 2.1b).  
Scheme 2.1 (a) Structure of DSP and reaction scheme for protein crosslinking 
and dissolution; (b) Structure of DIC and reaction scheme for protein crosslinking 
and dissolution 
 
2.4.2 Experiment section 
2.4.2.1 Materials  
 
Tyramine and 1'-Carbonyldiimidazole was purchased from Sigma Aldrich. 
DSP (Dithiobis[succinimidyl propionate]) were from Thermo Scientific. bis(2-
hydroxyethyl)ether  and 2-hydroxyethyl disulfide were purchased from Acros. 
2.4.2.2 Synthesis of cross-linker dithio-bis(ethyl 1 H-imidazole-1-
carboxylate) (DIC) and 2,2'-oxybis(ethane-2,1-diyl) bis(1H-imidazole-1-
carboxylate) (OEDIC) 
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A solution of 2-hydroxyethyl disulfide (1g, 6.48mmol) in chloroform (50 
mL) was added dropwise to a solution of 1,1'-Carbonyldiimidazole (10g, 61.67 
mmol) in chloroform (300 mL) under reflux (Scheme 2.2 A). The reaction mixture 
was stirred for 24 hours. The mixture was washed with cold water three times 
and the organic layer was dried with magnesium sulfate, filtered, concentrated 
and purified by column chromatography (EtOAc/chloroform=95:5) to give DIC 
(0.85g) as clear oil, which turned to white solid upon cooling.  The reaction of 
Bis(2-hydroxyethyl)ether (0.69g, 6.48mmol) with 1,1'-Carbonyldiimidazole (10g, 
61.67mmol) gave OEDIC (0.73g) as clear oil, which turned to white solid upon 
cooling (Scheme 2.2 B).  The synthesis and purification followed procedures 
described above for DIC.  
Scheme 2.2 Synthesis of cross-linker DIC (A) and OEDIC (B) 
 
2.4.2.3 Characterization of cross-linkers 
 
The compounds were dissolved in CDCl3 and their structures were 
characterized by NMR spectrometry (1H and 13C).  High-resolution mass 
spectrometry (Agilent technologies 6210 LC-TOF) was used to characterize the 
mass of the compounds. 
2.4.2.4 Synthesis of tyramine-cross-linker compounds  
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Tyramine (0.24g, 1.75mmol) was added to a solution of DIC (0.12g, 
0.35mmol) in isopropanol (15mL) (Scheme 2.3).  The reaction mixture was 
stirred for 24 h at 40°C. The mixture was concentrated and purified by column 
chromatography (EtOAc) to give tyramine-DIC (0.10g) as light yellow solid.  
Tyramine (0.24g, 1.75mmol) was added to a solution of DSP (0.14g, 0.35mmol) 
in DMF (4mL).  The reaction mixture was stirred for 24 h at 40°C.  The reaction 
was stopped by adding water (15 mL) to the reaction mixture.  Then the product 
was filtered and washed with water (10 mL) three times.  The product tyramine-
DSP (light yellow solid) was then dried and weighed (0.11g). 
 
Scheme 2.3 Synthesis of tyramine-DIC (a) and tyramine-DSP (b) 
 
2.4.2.4 Characterization of tyramine-cross-linker compounds 
 
The compounds were dissolved in acetone-D6 and their structures were 
characterized by NMR spectrometry (1H and 13C).  High-resolution mass 
spectrometry (Agilent technologies 6210 LC-TOF) was used to characterize the 
mass of the compounds. 
2.4.2.5 Degradation of tyramine-cross-linker compounds 
 
The products tyramine-DSP and tyramine-DIC were added to dithiothreitol 
solution (50 mM, PBS) at 37 °C and stirred for 24 h. Then the solutions were 
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lyophilized.   Isopropanol (1 mL) was added to the powder acquired and bath 
sonicated for 15 min.  The supernatants from the solutions were collected and 
analyzed by gas chromatography-mass spectrometry (Alilent Technologies 5975 
series MSD, 7820A GC system) and untreated tyramine was used as standard.  
Tyramine generated from tyramine-DIC was purified through thin layer 
chromatography (TLC) (EtOAc 90%, methanol 10%).  1H NMR and mass 
spectrometry (Agilent technologies 6210 LC-TOF) were used to confirm the 
structure of the compound. 
2.4.3 Results and discussion 
 
The successful synthesis of cross-linkers (DIC, OEDIC) and tyramine-
cross-linker compounds were confirmed by 1H NMR, 13CNMR and high-
resolution mass spectrometry (Table 2.2, 2.3).  
 
Table 2.2 Characterization of compounds by NMR 
 
Compound 
 
 
   NMR Condition 
 
 
Peak information 
 
DIC 1H, 400 MHz, CDCl3 
δ 8.18 (s, 2H), 7.45 (s, 2H), 7.11 
(s, 2H), 4.71 (t, J = 6.8Hz, 4H), 
3.11 (t, J = 6.4Hz, 4H) 
DIC 13C, 150 MHz, CDCl3 δ 36.3, 65.6, 117.2, 130.8, 137.1, 148.4 
OEDIC 1H, 600 MHz, CDCl3 
δ 8.17 (s, 2H), 7.43 (s, 2H), 7.10 
(s, 2H), 4.61 (t, J = 6.6Hz, 4H), 
3.89 (t, J = 7.2Hz, 4H) 
OEDIC 13C, 150 MHz, CDCl3 δ 66.5, 68.4, 115.9, 130.5, 137.0, 148.4 
Tyramine-DIC 1H, 400 MHz, actone-D6 
δ 7.07 (d, J=8.4Hz, 4H), 6.78 (d, 
J=8Hz, 4H), 4.28(t, J=7.6Hz, 4H), 
3.33 (q, J = 6.4Hz, 4H), 2.98 (t, J 
= 6.4Hz, 4H), 2.74(t, J=7.2Hz, 4H) 
Tyramine-DIC 13C, 100 MHz, actone-D6 δ 155.8, 130.1, 129.6, 115.2, 115.1, 62.0, 42.6, 37.8, 35.1 
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Tyramine-DSP 1H, 400 MHz, actone-D6 
δ 7.08 (d, J=8.4Hz, 4H), 6.78 (d, 
J=8.8Hz, 4H), 3.41(q, J=7.6Hz, 
4H), 2.98 (t, J = 7.2Hz, 4H), 
2.73(t, J=7.2Hz, 4H), 2.57(t, 
J=6.8Hz, 4H) 
Tyramine-DSP 13C, 100 MHz, actone-D6 δ170.4, 156.0, 130.0, 129.6, 115.3, 41.0, 35.4, 34.7, 34.4 
 
Table 2.3 Characterization of compounds by high-resolution mass spectrometry  
       
Compound 
 
    m/z 
 
 
  m/z (calculated) 
DIC 365.0346 (M+Na)+ 365.0354 (M+Na)+ 
OEDIC 317.0859 (M+Na)+ 317.0862 (M+Na)+ 
Tyramine-DIC 503.1274 (M+Na)+ 503.1287 (M+Na)+ 
Tyramine-DSP 471.1388 (M+Na)+ 471.1388 (M+Na)+ 
 
Compared to DSP, DIC has several advantages.  Imidazoles were 
introduced as the leaving groups in DIC to replace the highly reactive NHS as in 
DSP in order to better control the rate of the cross-linking reaction and the cross-
linking density on the particle surface.  Furthermore, DIC is a “traceless” 
reversible cross-linker, which does not leave any molecular pendants after 
disulfide cleavage (Scheme 2.1b).  Losing a stable five-membered ring structure 
is the driving force for this reaction cascade. 
To demonstrate the ability of DIC to release the amino group in its original 
form after cleavage of the disulfide, we utilized tyramine as a model, a small 
molecule with only one amino group.  Two tyramine molecules were reacted with 
DIC in isopropanol, which completely simulates the cross-linking conditions for 
protein-based particles (Scheme 2.3).  To prove this unique property of DIC, the 
commercially available disulfide cross-linker DSP was used as a control in this 
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study.  The dimer products were denoted as tyramine-DIC and tyramine-DSP, 
respectively. Both compounds were treated with 50 mM of dithiothreitol (DTT) in 
phosphate buffer saline (PBS) to cleave the disulfide bond.  Gas chromatography 
mass spectrum (GC-MS) results indicated that after cleavage of the disulfide 
bond, tyramine was regenerated from tyramine-DIC. No peak of tyramine was 
observed with tyramine-DSP (Figure 2.7).  In addition, 1H-NMR and high-
resolution mass spectrometry confirmed the structure of tyramine recovered after 
DTT treatment of tyramine-DIC. (Table 2.4) Therefore, all the aforementioned 
results support the successful design of the novel DIC cross-linker. 
             
Figure 2.7 GC-MS characterization of tyramine-DIC and tyramine-DSP after 
treatment with DTT, (a) standardard tyramine, (b) tyramine-DIC, (c) tyramine-
DSP. The peak at 5.899 min (m/z=152.0) in (b) and (c) represents oxidized DTT.  
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Table 2.4 Characterization of tyramine by 1H NMR and high-resolution mass 
spectrometry 
 
Compound 
 
1H NMR (400 MHz, MeOD)        MS (m/z) a 
Tyramine standard 
δ 7.02 (d, J=4.2 Hz, 2H), 6.71 (d, J=4.2 
Hz, 2H), 2.81 (t, J = 7.2 Hz, 2H), 2.65(t, 
J=7.2 Hz, 2H) 
138.0914 (M+H)+ 
Tyramine 
generated from 
tyramine-DIC 
δ 7.02 (d, J=4.2 Hz, 2H), 6.71 (d, J=4.2 
Hz, 2H), 2.82 (t, J = 7.2 Hz, 2H), 2.65(t, 
J=7.2 Hz, 2H) 
138.0916 (M+H)+ 
 
a m/z calculated for tyramine [M+H]+=138.0919 
2.4.4 Conclusions 
 
A novel disulfide-based cross-linker was synthesized and the structure 
was confirmed by 1H-NMR, 13C-NMR and MS. By using tyramine as a model 
molecule, DIC demonstrated the ability to release the amino group in its original 
form after cleavage of the disulfide, a benefit over commercially available protein 
cross-linker DSP.  
2.5 Stabilization of Protein Particles with Cross-linker DIC 
 
2.5.1 Introduction 
 
Having successfully fabricated protein-based particles using PRINT 
technology and synthesized the disulfide-based cross-linker DIC, the cross-linker 
was applied to stabilize the protein-based particles transiently. This method is 
ideal for utilizing the protein-based particles for therapeutic applications 
especially for RNA replicon delivery.  
2.5.2 Experimental section   
 
51 
2.5.2.1 Materials    
 
Bovine serum albumin was from Calbiochem. Alexa fluor 555® labeled 
bovine serum albumin was purchased from invitrogen. Bovine albumin ELISA 
quantitation set was purchased from Bethyl Laboratories, Inc. α-D-Lactose, 
glutathione and glycerol, were purchased from Acros. Cross-linkers DIC and 
OEDIC were synthesized as previously described.  
2.5.2.2 Prepartion of cross-linked protein particles 
 
The Alexa fluor 555® labeled protein particles (1µm × 1µm, cylindrical) 
were prepared as previously described in section 2.3.2.2. The particle 
concentration in isopropanol was determined by Thermal Gravimetric Analysis 
(TGA) (TA Q5000). Based on the TGA results, an appropriate amount of 
isopropanol was added to the particle dispersion to achieve a particle 
concentration of 1mg/mL. To 850 µL of particle dispersion, cross-linkers (1.275 
mg, 1.913 mg, 2.869 mg of DIC, corresponding to 4.4 mM, 6.6 mM and 9.9 mM 
in the final solution, 1.096 mg of OEDIC corresponding to 4.4 mM in the final 
solution) was added. The resulting dispersion was shaken on a vortex machine 
for 24 h at 40 °C. The reaction was terminated by centrifuging particles down for 
3 minutes, followed by removal of the supernatant containing the cross-linker and 
adding 850µL of isopropanol. The particles were washed three times with 
isopropanol by centrifugation to remove the excess cross-linkers and then 
resuspended in water.  
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2.5.2.3 Characterization of cross-linked particles using SEM, DLS and 
Zeta-sizer 
 
The PRINT particles were imaged by a scanning electron microscopy 
(Hitachi modelS-4700) and the hydrodynamic diameters of the PRINT particles 
were measured by dynamic light scattering (Brookhaven Instruments Inc., 
90Plus).  For zeta potential measurements, the particles were dispersed in 1 mM 
potassium chloride at a concentration of 20 µg/ml and tested by a Zetasizer Nano 
Analyzer (Malvern Instruments Inc., Nano Zetasizer). 
2.5.2.4 Particle dissolution profile measurements 
 
The release of Alexa Fluor® 555-conjugated BSA was used to 
characterize the dissolution rate of the particles.  The cross-linked particles were 
resuspended in water to achieve a particle concentration of 1.33 mg/mL.  To 
each mini dialysis unit (purchased from Fisher Scientific, MWCO 20K), 75 µL of 
particle solution was added.  Typically, 24 units were dialyzed against 1 L of 
Phosphate Buffers Saline solution (PBS) containing 5 mM glutathione with a 
magnetic bar stirring gently at the bottom of the beaker.  Another 24 units were 
dialyzed against 1 L of PBS buffer without glutathione as controls.  The dialysis 
process was carried out in a 37 °C incubator. At different time points (0 h, 1.5 h, 
3 h, 5 h, 12 h, 24 h, 48 h), one unit was withdrawn from each bath.  The particle 
solution was recovered from the units and each unit was washed with 75 µL of 
PBS.  The wash was combined with recovered particle solution and appropriate 
amount of PBS was added to achieve a total mass of 200 mg.  The solution was 
centrifuged at 14000 rpm for 10 min.  The supernatant was measured for 
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fluorescence (excitation 545 nm, emission 575 nm) by a SpectraMax M5 plate 
reader (Molecular Devices).  The fluorescence from PBS was used as 
background and the fluorescence from un-cross-linked particles (0.5 mg/mL in 
PBS) was used as a 100% control.  
2.5.2.5 Albumin binding activity after particle dissolution 
 
The BSA particles were cross-linked at 4.4 mM of DIC for 24 h at 40°C 
and incubated in PBS containing 5mM GSH for 5 h.  The solution was then 
dialyzed against water for 2 h to remove GSH.  The concentration of BSA was 
quantified by BCA assay and standard sandwich ELISA assays for BSA (Bethyl 
Laboratories, Montgomery, TX) were conducted following the protocol provided 
by the vendor.  Absorbance was measured with a SpectraMax M5 plate reader 
(Molecular Devices) at 450 nm. 
2.5.2.6   Study of the depth of cross-linking reaction on particles 
 
The cross-linking of the particles was performed after PRINT process. The 
goal of this study is to determine if the cross-linking also occurs in the center of 
the particles. A macroscopic film that is prepared on PET sheet from 36.5 wt% of 
BSA, 1 wt% of Alexa fluor 555 labeled BSA, 37.5 wt% of lactose and 25 wt% of 
glycerol, the same composition as the PRINT particles used in this study. The 
film is shown in orange and PET is shown in gray. The film was washed with 
isopropanol three times in order to mimic the particle fabrication process and 
then reacted with DIC at 4.4 mM of cross-linker concentration for 24 h at 40 °C.  
Then the film was collected with PBS using cell scraper. The solution was 
vortexed for 1 h and centrifuged down for 10 min at 14000 rpm to remove the 
cross-linked material.  The supernatant was analyzed using fluorescence 
spectrometry for the amount of free protein and the percentage of free protein 
was calculated using un-cross
2.5.3 Results and discussion
 
The stabilization of PRINT albumin particles in aqueous solutions was 
achieved by introducing DIC which reacts with the amine groups on the surface 
of protein molecules (Figure 2
cross-linker can take advantag
and selectively release encapsulated cargo when they reach cytoplasm.  As a 
control, a non-disulfide non
bis(1H-imidazole-1-carboxylate) (OEDIC) was also
control (Figure 2.8 B). 
 
Figure 2.8 SEM images of BSA particles after incubation with water. (A) Particles 
were cross-linked at 4.4 mM of DIC, (B) particles were cross
OEDIC.  
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-linked film as 100% control.  
 
.8 A). Particles cross-linked with this disulfide 
e of the high concentration of intracellular GSH 
-degradable cross-linker, 2,2'-oxybis(ethane
 synthesized and used as a 
-linked at 4.4 mM of 
-2,1-diyl) 
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BSA particles were crosslinked with DIC and OEDIC at different cross-
linker concentrations (based on a constant particle concentration). The cross-
linked PRINT protein particles were characterized by dynamic light scattering 
(DLS) and ζ-potential analyzer.  The particles displayed a hydrodynamic 
diameter around 1 micron and a narrow polydispersisity (Table 2.5). Because the 
isoelectric point of BSA is around 4.75, crosslinked BSA particles showed a 
slightly negative ζ-potential. Particles cross-linked at higher cross-linker 
concentrations showed more negative ζ-potentials due to less free amino groups 
on the particle surface. 
 
Table 2.5 Characterization of cross-linked BSA particles a 
 
 
Diameter, b nm 
 
PDI c ζ-Potential, d mV 
DIC-4.4 mM 
   1201 ± 152 0.016       -13.6 ± 0.5 
DIC-6.6 mM 
   1164 ± 393 0.114       -16.3 ± 1.0 
DIC-9.9 mM 
   1069 ± 346 0.105       -23.1 ± 0.4 
OEDIC-4.4 mM 
   1069 ± 362 0.114       -10.9 ± 0.3 
a
 The particles fabricated for dissolution study. DIC-4.4 mM: particles cross-linked 
with DIC at 4.4 mM. DIC-6.6 mM: particles cross-linked with DIC at 6.6 mM.  
DIC-9.9 mM: particles crosslinked with DIC at 9.9 mM. OEDIC-4.4 mM: particles 
cross-linked with OEDIC at 4.4 mM. b Hydrodynamic diameter measured by 
dynamic light scattering.  The average hydrodynamic diameters were obtained 
from three measurements.  The error bars are the half-width of the effective 
diameters. c Polydispersity index from the dynamic light scattering 
measurements. d ζ-potential was measured in 1mM KCl by Zetasizer.  The error 
bars are standard deviations from three measurements.  
 
A quantitative study of particle dissolution was performed.  The GSH 
concentration in cytoplasm of cells ranges from 1 to 15 mM.23  In this study, PBS 
containing 5 mM GSH and PBS only were used to simulate intracellular and 
extracellular environment, respectively.  In order to monitor the degradation of 
albumin particles, 1 wt% of BSA Alexa Fluor® 555 conjuga
into the particles and the amount of this dye
particles upon particle dissolution was measured using fluorescence 
spectroscopy (Figure 2.9).  A plot of Alexa Fluor® 555 conjugate release versus 
time for particles cross-linked with DIC at 4.4 mM showed an accelerated rate of 
dissolution when dispersed in PBS with 5 mM GSH.  The same particles 
dispersed in PBS only showed minimal dissolution at 48 h.  Under identical 
conditions, particles cross-
PBS with and without GSH.  Particles cross
dissolved preferentially in PBS with GSH, but the rate was noticeably slower than 
particles cross-linked using 4.4 mM of DIC.  When parti
with the DIC cross-linker at 9.9 mM, very minimal dissolution of particles was 
observed both in PBS with GSH and PBS only during a 48
 
             
Figure 2.9 Dissolution profile of cross
mM GSH (GSH) and PBS only (PBS), A: particles cross
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te was incorporated 
-conjugated protein released from 
linked with OEDIC showed no noticeable difference in 
-linked with the DIC at 6.6 mM also 
cles were cross
-h time frame. 
-linked BSA particles in PBS containing 5 
-linked at 4.4 mM of DIC, 
-linked 
 
 
B: particles cross-linked at 6.6 mM of DIC, C: particles cross
DIC, D: particles cross-linked at 4.4 mM of OEDIC. Squares with solid lines 
represent 5 mM GSH containing PBS and triangles with dotted lines represent 
PBS only. The error bars stand for the standard deviation calculated from three 
wells. 
 
Fluorescence microscopy was also used to further investigate the integrity 
of particles cross-linked with DIC and OEDIC at 4.4 mM of cross
concentration (Figure 2.10
From these data, it was apparent that the particles cross
disulfide linker DIC preferentially dissolved under reducing conditions and the 
rate of particle dissolution can be effectively modulated by changing the cross
linker concentration used.  Alternatively, the cross
be used as a parameter to fine tune the particle cross
release profiles.  
                  
Figure 2.10 Particle dissolution by microscopy image at 5
Particles cross-linked with 4.4 mM of DIC, in PBS, (B) Particles cross
4.4 mM of DIC, in PBS containing 5 mM of GSH,  (C) Particles cross
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-linked at 9.9 mM of 
).    
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-linking reaction time can also 
-linking densities and 
 
-h time point.  (A) 
-linker 
-
-linked with 
-linked with 
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4.4 mM of OEDIC, in PBS (D) Particles cross-linked with 4.4 mM of OEDIC, in 
PBS containing 5 mM of GSH 
 
In this proof-of-concept study, we are also interested in the integrity of 
BSA after fabrication and crosslinking process, because it may lead to the 
delivery of therapeutic proteins of interest using this strategy.  To evaluate the 
biological integrity of the protein after dissolution of the DIC cross-linked 
particles, enzyme-linked immunosorbent assays (ELISA) were performed on 
native BSA and BSA released from DIC-cross-linked PRINT BSA particles in 
PBS with 5mM glutathione, as well as heat denatured BSA.  Several 
concentrations were compared over the sampling range of the assays (Figure 
2.11). The results of the assay indicated that the albumin dissolved from the 
cross-linked particles (squares) had very similar absorbance in the ELISA assay 
as the native albumin (triangles).  The denatured free protein (tilted squares) 
showed significantly less total absorbance compared to free protein and 
dissolved particles.  ELISA relies upon protein-protein interactions, thus providing 
insight into the preservation of the protein’s binding motifs.  The ELISA data 
illustrated that antibody recognition and protein binding ability of BSA are 
minimally affected in the PRINT and cross-linking process for albumin. 
 
Figure 2.11 The BSA activity measured by ELISA. Square represents BSA 
released from DIC-cross-
BSA, and tilted square represents heat
 
The cross-linking depth in one dimension can be determined. If the cross
linking occurs close to the bottom of the 
protein can be released after the cross
reaction only occurs at the
instantaneously dissolve upon exposure to PBS. 
Films with thicknesses of 200 nm, 500 nm and 1.6 µm after 24 h of cross
linking reaction and films with a thickness of 500 nm for 4 h and 14 h of cros
linking reaction were examined. Each experiment was done in triplicate. 
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linked PRINT particles, triangle represents untreated 
-denatured BSA.  
a macroscopic film, minimal of free 
-linking reaction. If the cross
 surface of the film, the free protein in the center will 
 
 
-
-linking 
-
s-
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Figure  2.12 Percentage of dissolution of macroscopic films of different thickness 
and cross-linked for different length of times 
 
Figure 2.12 showed that after 24 hour of cross-linking reaction, the films 
with thicknesses from 200nm to 1.6 µm all showed minimal dissolution, indicating 
that the film was cross-linked at the bottom of the film and the cross-linking 
reaction can penetrate at least 1.6 µm in one dimension.  At 4-h and 14-h, the 
500nm film was only partially cross-linked.  
Based these results, we can come to the conclusion that the cross-linking 
reaction occurs at the center of the 1-micron cylindrical particles. 
2.5.4 Conclusions       
 
From these data, it was apparent that the particles cross-linked with the 
disulfide linker DIC preferentially dissolved under reducing conditions and the 
rate of particle dissolution can be effectively modulated by changing the cross-
linker concentration used.  Alternatively, the cross-linking reaction time can also 
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be used as a parameter to fine tune the particle cross-linking densities and 
release profiles. The ELISA data showed that antibody recognition and protein 
binding ability of BSA are minimally affected in the PRINT and cross-linking 
process for albumin. 
2.6 Summary of conclusions and recommendation for future work 
 
In summary, a novel method for the fabrication of protein (BSA) particles 
that uses a novel cross-linker strategy was able to effectively render the particles 
transiently insoluble in aqueous solutions.  This particle fabrication method built 
on PRINT technology platform allows for the fabrication of particles of controlled 
sizes and shapes.  A disulfide cross-linker for the stabilization of the particles 
was synthesized and applied on the particles.  The particles cross-linked with the 
cross-linker preferentially dissolved under reducing conditions and the rate of 
particle dissolution can be controlled by adjusting the cross-linker concentration 
used. These results suggested that these precisely engineered protein particles 
can be used as carriers for nucleic acids like RNA replicon. In addition, the 
antibody recognition and protein binding ability of BSA were minimally affected in 
the PRINT and cross-linking processes, indicating that this method could be 
applied to delivery of functional proteins to the cytoplasm of cells.  
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 CHAPETER 3 
 
RNA REPLICON DELIVERY VIA PROTEIN-BASED PRINT     PARTICLES: 
IMPLICATIONS FOR NUCLEIC ACID VACCINE
 
3.1 Introduction 
 
The use of RNA replicons for vaccines, as previously mentioned, is a 
nucleic acid-based method to express antigens in the cytoplasm of host cells and 
has great promise to trigger effective immune responses against a variety of 
diseases. To test the efficacy of the protein-based particles that can be rendered 
transiently insoluble in extracellular environment and preferentially dissolve in 
intracellular environment, RNA replicons were explored as the active cargo for 
intracellular delivery.  
The delivery of RNA replicons require that the cargos be delivered to the 
cytoplasm of host cells and the drug delivery system faces both anatomical and 
cellular barriers. Depending on the administration route, the delivery vector may 
encounter serum proteins, nucleases, macrophages and clearance by the 
reticuloendothelial system (RES) that will disable the vector from reaching their 
target. Once at the tissue of interest, the delivery vector must enter the cell 
through endocytosis pathways or protein transduction domains such as TAT 
peptides.1 And depending on the cell uptake mechanism, the vector may have to 
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follow the endo-lysosomal pathways and the vector has to escape the endosomal 
compartment and get into the cytoplasm before being degraded in a lysosome.  
Particles have to be designed to meet all the aforementioned criteria to 
successfully deliver the RNA replicon in vivo. Frequently a cationic component 
was introduced into the particle to: 1) facilitate cell uptake through electrostatic 
interactions between positively charged particles and negatively charged cell 
membrane, 2) promote endosomal escape and particle transfection through the 
“proton sponge effect” or destabilization of endosomal membranes.  
Protein-based particles have been used for gene delivery. Several groups 
reported the strategy to incorporate poly (ethylene imine) (PEI) into protein-based 
particles, which achieved successful delivery of siRNA2 and plasmid DNA3,4.  
Another strategy reported was to prepare particles from cationized protein which 
may function the same way as other cationic polymers do in facilitating cell 
uptake and endosomal escape.5 However, some research groups reported 
successful transfection of cationized protein particles and delivery of gene cargos 
6, 7, 8, 9 while some groups reported that the cationized protein achieved only low 
transfection efficiencies and cells needed to be treated with choloroquine to 
achieve endosomal escape.5  
A RNA replicon is, by nature, a piece of messenger RNA (mRNA) with 
replication features. The non-viral delivery of mRNA using cationic lipids 
including 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA),10 N-[1-
(2,3-dioleoloxy)propyl]-N,N,N-trimethyl ammonium chloride (DOTAP)11, 12, 13, 14 
etc. has been described. The DOTAP-based lipoplexes were the most effective 
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one in delivering mRNA and so far showed the highest activity according to most 
published reports. Enhancement of protein expression of the DOTAP-mRNA 
system was also achieved through incorporation of an inorganic nano-apatite,15 
and  modification of the mRNA structure.13 The use of polycations for delivery of 
mRNA, however, is not as widely studied as compared with plasmid DNA and 
siRNA. Only several cationic polymers including DEAE-dextran,10 poly(L-lysine) 
(PLL)16  and dendrimers17 have been used to complex and deliver mRNA. 
Bettinger T. et al. compared several synthetic vectors including PEI (25 kDa and 
2 kDa), PLL (54 kDa and 3.4 kDa), and a short polycation melittin in mRNA 
transfection. 14 The results indicated that PEI 25 kDa and PLL 54 kDa were not 
able to mediate protein expression in a cell-free translation assay following 
cytoplasmic injection into cells, probably due to binding that was too strong 
between the mRNA and the polycations and free mRNA could not be released to 
enable the expression of protein (Figure 3.1). In contrast, PEI 2 kDa and PLL 3.4 
kDa could give high protein expression but were dependent on chloroquine for 
successful transfection. And when a melittin peptide was conjugated to PEI 2 
kDa, the lipoplex formed with mRNA mediated efficient translation of mRNA in 
cells.  The issue of effective transfection and release of mRNA by polycations 
was also accessed by cross-linking low Mw polycations using a reducible linker 
which can be cleaved by the intracellular reducing environment.18 Instead of 
complexing the mRNA with cationic polymers, Su X. et al. developed a strategy 
to complex mRNA to the surface of cationic, core-shell structured nanoparticles 
with a poly(β-amino ester) (PBAE) core enveloped by a phospholipid bilayer 
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shell.19 This system achieved delivery of mRNA both in vitro and in vivo with 
minimal toxicity and demonstrated the advantage of particles in mRNA delivery.  
Figure 3.1 Proposed intracellular fate of delivered mRNA, adapted from [14]. 
 
Based on the aforementioned studies of protein-based particles for gene 
delivery and non-viral vectors for mRNA delivery, we designed two strategies to 
deliver an RNA replicon with the PRINT protein particle.  
1) Cationized BSA (cBSA) was used as the particle matrix. The cationic 
protein may be able to facilitate internalization of particles in the cells and 
transfection of particles, potentially releasing the cargo once in the cytoplasm of 
cells.  
2) Normal BSA was used as the particle matrices. The negative-charged 
particles could then be decorated with the cationic agents that can facilitate cell 
uptake and particle transfection.  
Model RNA replicon encoding for chloramphenicol acetyl transferase 
(CAT), green fluorescence protein (GFP), and Luciferase protein were chosen in 
this study because CAT, GFP and Luciferase proteins are exogenous for 
mammalian cells and the assays to quantify the activity of those three proteins 
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have been well established. CAT is a bacterial enzyme and Luciferase is an 
enzyme that catalyzes luminescent reactions and has been widely used in non-
invasive bioluminescence imaging research. RNA replicons endcoding for the 
GFP protein was chosen due to the fact that GFP protein exhibits bright green 
fluorescence when exposed to ultraviolet blue light, which can be easily 
visualized with fluorescent microscope. 
3.2 Incorporation of RNA Replicon into BSA Particles  
3.2.1 Introduction 
 
Normal BSA was chosen as the particle matrix since the RNA replicon and 
BSA are both readily soluble in aqueous solutions and negative-charged 
molecules in water. RNA replicon and protein appear to be perfectly miscible and 
could subsequently be molded into particles utilizing PRINT technology when 
appropriate plasticizers and process aids (lactose and glycerol) were used. 
Based on previous studies, DCs, the target cell for RNA replicon based vaccines, 
were found to preferentially take up micron-sized particles.20, 21 In this study, 
cylindrical particles with both diameter and height as 1 µm were fabricated.  
3.2.2 Experiment Section 
3.2.2.1 Materials and cell culture 
 
Bovine serum albumin was from Calbiochem. BCA protein assay reagent 
was from Thermo Scientific. Quant-iT TM RNA assay kit was purchased from 
invitrogen. Lactose assay kit was purchased from Abcam. TransIT®-mRNA 
transfection kit was purchased from Mirus. α-D-Lactose and glycerol were 
purchased from Acros.  
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Vero cells were maintained at 37 °C in an atmosphere containing 5% CO2. 
The cells were grown in Minimum Essential Medium (MEM; Invitrogen, Carlsbad, 
CA) supplemented with 5% fetal bovine serum (FBS, HyClone, Logan, UT), MEM 
non-essential amino acid solution (Invitrogen) and antibiotic–antimycotic 
(Invitrogen).  
Replicon Plasmid Construction: Plasmids containing the reporter genes 
chloramphenicol acetyltransferase (CAT), Fire Fly Luciferase (Luc2), and Green 
Fluorescent protein (GFP) were purchased from Promega (CAT # E187A, Luc2 
#E6651, GFP #E642). These genes were PCR amplified using iProof™ HF 
Master Mix Taq polymerase (BioRad), and gene specific primers containing AscI 
and PacI restrictions sites for sub-cloning.  The PCR products were cloned into 
an intermediate vector for nucleotide sequence verification, pCR®4 Blunt-TOPO 
(Life Technologies # K2875-40). Upon sequence confirmation the PCR 
fragments were sub-cloned into an DNA plasmid constructed to contain the 
following elements: a T7 RNA polymerase promoter for in vitro RNA transcription; 
the 5’ untranslated region, nonstructural protein genes, 26S promoter, and the 3’ 
untranslated region of Venezuelan Equine Encephalitis Virus (VEE). Specifically 
the PCR products and the replicon plasmid base vector were digested with AscI 
and PacI restriction enzymes. The PCR products were ligated using T4 DNA 
Ligase into the AscI and PacI restriction enzyme sites contained in the multiple 
cloning site of the replicon plasmid.  
RNA production: the replicon plasmid was linearized with Not I restriction 
enzyme and used as template for in vitro transcription of capped replicon RNA 
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utilizing the T7 RiboMAX™ Express Large Scale RNA Production System 
(Promega #P1320) supplemented with 7.5 mm methyl G CAP analog (Promega 
#P1711). Replicon RNA was purified using the SV Total RNA Isolation System 
(Promega #Z3101) as specified by the manufacturer. 
3.2.2.2 Preparation of RNA replicon loaded BSA-based particles 
 
The bovine serum albumin (BSA) PRINT particles were derived from a 
mixture composed of 37.0 wt% of BSA, 37.0 wt% of lactose, 25.0 wt% of glycerol 
and 1.0 wt% of RNA replicon. A 7.8 wt% solution of this mixture in water was 
prepared and then cast as a film onto a poly(ethylene terephthalate) (PET) sheet. 
Water was removed with a heat gun moving back and forth.  The film was 
laminated onto a piece of PRINT mold (2 × 4 inch, cylindrical, d =1 µm, h = 1 µm, 
mold No.: MMM-262-090A, MMM-369-070), forming a sandwich structure with 
the film in the middle. The mold was delaminated by passing the mold and the 
PET through a heated laminator with a temperature of 60 °C or 148 °C on the top 
roller and a pressure of 80 psi between the rollers. The filled mold was 
relaminated onto a sheet of plasdone covered PET. The laminated mold and 
PET were passed through the heated laminator again. After the particle filled 
mold cooled down, the mold was removed gently and all the PRINT particles 
were transferred from the mold to the plasdone-covered PET. The particles were 
harvested from the PET by dissolving plasdone with isopropanol. The harvested 
particles were washed with isopropanol for three times by centrifugation to 
remove plasdone. The particles were finally dispersed in isopropanol and the 
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particle concentration was determined by Thermal Gravimetric Analysis (TGA) 
(TA Q5000). 
3.2.2.3 Scanning electron microscopy (SEM) 
 
For visualization samples were coated with 2 nm gold palladium alloy 
using a Cressington 108 auto sputter coater. Images were taken at an 
accelerating voltage of 2 kV using a Hitachi model S-4700 scanning electron 
microscope (SEM).  
3.2.2.4 Quantification of BSA, lactose and RNA replicon in particles prior to 
cross-linking  
 
Particles were dissolved in water. BCA assay (Thermo scientific) was 
used to quantify the amount of BSA in the solution and a lactose quantification kit 
(Abcam) was used to quantify the amount of lactose in the solution. Quant-iT TM 
RNA assay kit (Invitrogen) was used to quantify the amount of RNA in the 
solution. The assays were performed according to vendor’s instructions and each 
assay was done in duplicate and three independent samples were measured.  
3.2.2.5 RNA replicon extraction from un-cross-linked particles particles 
 
For particles prior to cross-linking, 50 µL of PBS was added to dissolve 
0.15 mg of particles. A Qiazol-chloroform extraction procedure was used to 
extract RNA replicon from the RNA replicon-BSA mixture. Typically: 
1) Chloroform (200 µL) was added to 50 µL of samples and mixed through 
inversion and then incubated at room temperature for 5 min. 
2) 1 mL of Qiazol (from invitrogen) was added to the vial and mixed 
through inversion and then incubated at room temperature for 5 min. 
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3) The vial was centrifuged at 10600 rpm at 4 °C for 15 min. 
4) The aqueous phase was taken out and put in a new vial. Then 500 µL 
of isopropanol and 2 µL of Glycoblue (Ambion) were added and mixed well. 
5) The sample was then incubated at room temperature for 10 min and 
then centrifuged at 10600 rpm at 4 °C for 10 min.  
6) The supernatant was removed and the blue pellet was washed with 1 
mL of 75% ethanol. The vial was centrifuged at 8600 rpm at 4 °C for 5 min. 
7) Ethanol was removed and the blue pellet was dissolved in 20 µL of 
DEPC-treated water.  
3.2.2.6 Agarose gel electrophoresis 
 
Agarose gel was prepared by dissolving agrasose in 1× NorthernMax®-
Gly gel preparation and running buffer (Ambion) at 1 wt%.  Typically, 5 µL of 
sample (RNA replicon extracted) was mixed with 5 µL of water and 10 µL of 
NorthernMax®-Gly load dye (Ambion) and heated at 50 °C for 10 min before 
loading onto the gel. The gel was then run in 1× NorthernMax®-Gly gel 
preparation and running buffer (Ambion) at 70 V for 35 min before being imaged 
by a GE ImageQuant LAS 4000 biomolecular imager.  
3.2.2.7 Evaluation of RNA replicon activity through CAT expression 
 
Typically, 2×104 Vero cells were plated into 24 well tissue cultured treated 
plates 18-24 h prior to assay. Vero cells were transfected with CAT RNA replicon 
utilizing the TransIT® mRNA transfection kit (Mirus Bio, Madison, WI) following 
the manufacturer’s protocol. Typically, for every well on a 24-well plate, the RNA 
replicon were mixed with 2 
Boost reagent and dosed to cells.
transfection and CAT ELISA (Roche, Indianapolis) analysis was carried out 
according to the manufacturer's instructions. The r
calculated using following method:
  
Where Ar: the relative absorbance 
Aa: the absorbance acquired by plate reader at 405 nm for samples dosed 
with RNA replicon or particles
Ac: the absorbance acquired by plate reader at 405 nm for
3.2.3 Results and Discussion
 
Based on our previous success, RNA replicon was incorporated into the 
particle by mixing the cargo with BSA
Following the aforementioned PRINT process, cylindrical BSA particles with both 
diameter and height as 1 µm were fabricated with a preparticle composition 
containing 37 wt% of BSA, 37 wt% of 
of RNA replicon (Figure 3.2)
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µL of TransIT-mRNA reagent and 1 µ
 Cell lysates were prepared 48h post
elative absorbance was 
 
 
 
 untreated cells
 
, lactose and glycerol (Figure 2.3
α-D-lactose, 25 wt% of glycerol and 1 wt% 
.  
L of mRNA 
-
 
). 
                  
Figure 3.2 PRINT BSA particles loaded with 1 wt% of CAT RNA replicon.  Scale 
bar represents 20 µm 
 
The RNA replicon is a single stranded RNA with low stability. Maintaining 
its integrity during the PRINT process is essential
temperature used for particle fabrication on the biological activity of RNA 
replicon. Typically, 1 wt% of CAT RNA replicon was charged into cylindrical 
albumin particles (d = 1 µm, h = 1 
laminator roller: 60°C vs. 148
buffered saline (PBS) and followed by extraction of RNA replicon from the BSA
RNA replicon mixture. It should be noted that the particles used in this 
experiment did not involve any cross
a control, the RNA extraction procedure was also performed on the blank 
particles to rule out any existence of RNA in the BSA used for particle fabrication.  
The integrity of the extracted RNA repl
electrophoresis, as shown in Figure 3.3
RNA replicon encapsulated at 60
as the untreated RNA replicon.  However, when particles 
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. We studied the influence of 
µm) by using two temperatures on the he
°C. The particles were dissolved in phosphate 
-linking and were readily soluble in water. As 
icon was first evaluated using agarose gel 
. Electrophoresis analysis showed that 
°C displayed a tight band at the same position 
were fabricated at 
ated 
-
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148°C, only some smears, which were speculated as RNA replicon degradation 
products, were observed.  
                                    
Figure 3.3 Agarose gel of RNA replicon before and after particle crosslinking. 1: 
RNA ladder, 2: untreated RNA 200 ng, 3: untreated RNA 100 ng, 4: RNA replicon 
extracted out of blank BSA particles, 5:RNA replicon extracted out of BSA 
particles fabricated at 148°C, 6: RNA replicon extracted out of BSA particles 
fabricated at 60°C 
 
The integrity of extracted RNA replicon was further accessed by a CAT 
ELISA assay after RNA replicon was transfected into Vero cells, a kidney 
epithelial cell line developed from an African green monkey, using a TransIT-
mRNA transfection reagent (TransIT).  The CAT ELISA assay quantifies the 
amount of CAT protein generated by the cells after RNA replicon transfection. 
Results showed that RNA replicon encapsulated at 148°C showed very minimal 
biological activity and RNA extracted from particles fabricated at 60°C produced 
similar protein expression levels to untreated RNA replicon control (Figure 3.4). 
The results showed that RNA replicon is very sensitive to the temperature used 
for particle fabrication and lower temperature is preferred to preserve RNA 
replicon activity. 
Figure 3.4 Relative absorbance
un-treated cells (cells only) were defined as 1. Error bars represent standard 
deviation calculated from four wells.
 
After the harvest and purification steps using isopropanol, the par
fabricated at 60°C were determined to contain 1.5
purification step in the final harveste
particles of this size (d = 1 
copies of the RNA replicon per particle (calculated based on a particle density of 
0.8 g/mL).  
 
Table 3.1 Composition of RNA replicon
 
BSA 
Lactose 
Glycerol 
RNA Replicon 
a
 The weight percentage of components charged into the preparticle solution that 
was then drawn into a film on the PET sheet. 
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 obtained from CAT ELISA. The absorbance from 
 
±0.1 wt% of RNA replicon after 
d particle composition (Table 3.1
µm, h = 1 µm) this equals to approximately 1500 
-loaded BSA particles  
Charged Composition a  
(wt%) 
Final Composition 
(wt%) 
37.0 81.5±.0.2 
37.0 10.3± 3.1 
25.0 6.7± 2.8 
1.0 1.5±0.1 
bFinal particle composition after 
 
ticles 
). For 
b 
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harvest and purification step.  The errors stand for standard deviation calculated 
from three experiments.  
 
3.3 RNA Replicon Integrity in the Process of Cross-linking 
3.3.1 Introduction 
 
 In order to successfully deliver the RNA replicon, it is essential to retain 
the bioactivity of this relatively fragile molecule throughout the whole process of 
fabrication, stabilization, and delivery.   The previous results have shown that the 
fabrication process is RNA-friendly and does not abolish the activity of RNA 
replicon. The next step is to evaluate the activity of RNA replicon after the cross-
linking process.  
Dithio-bis(ethyl 1 H-imidazole-1-carboxylate) (DIC) was used as the cross-
linker to stabilize the protein particles in aqueous solutions. This cross-linker, 
compared to DSP, has several advantages for protein particle stabilization for 
RNA replicon delivery. Imidazoles as the leaving groups enhanced the reaction 
selectivity for amines over hydroxyl groups compared to NHS esters, which is 
essential to maintain the integrity of RNA replicon in the cross-linking procedure. 
Furthermore, DIC is a “traceless” reversible cross-linker, which does not leave 
any molecular pendants after disulfide. A truly reversible chemistry has many 
benefits for the delivery of RNA replicon. It releases the amino groups in its 
original form and avoids the unknown immune response towards novel antigens. 
Additionally, even if the amine functionalities on nucleobases were cross-linked 
by DIC, due to the fully reversible nature of the cross-linker, the nucleobases 
should revert to its original state upon disulfide cleavage if DIC is used. Despite 
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of all the advantages of the DIC, this cross-linker has to be evaluated for its 
compatibility with the RNA replicon. 
3.3.2 Experimental section 
3.3.2.1 Materials 
 
Bovine serum albumin was from Calbiochem. α-D-Lactose, dithiothreitol 
(DTT) and glycerol were purchased from Acros. DIC was synthesized as 
described in section 2.3.2.2.  Cells were cultured as described in section 3.2.2.1.  
3.3.2.2 Cross-linking of CAT RNA replicon loaded particles 
 
The 1 µm cylindrical BSA particle particles containing CAT RNA replicon 
were prepared as described in section 3.3.2.2. Based on the TGA results, an 
appropriate amount of isopropanol was added to the particle dispersion to 
achieve a particle concentration of 1mg/mL. To 850 µL of particle dispersion, 
cross-linker (1.275 mg, corresponding to 4.4 mM of DIC in the final solution) was 
added. The resulting dispersion was shaken on a vortex machine for 24 h at 40 
°C. The reaction was terminated by centrifuging particles down for 3 minutes 
using a minicentrifuge (Thermo scientific), followed by removal of the supernatant 
containing the cross-linker and adding 850µL of isopropanol. The particles were 
washed three times with 850µL of isopropanol by centrifugation to remove the 
excess cross-linkers and then aliquoted into 150 µg/vial. The particles were 
pelleted   down through centrifugation and 10 µL of isopropanol was added to the 
vial to protect the particles from drying out. The particles were stored in -80 °C 
freezers until further use.  
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3.3.2.3 Particle imaging 
 
The PRINT particles were incubated in PBS for 4h. The particles were 
then washed with isopropanol and deposited on glass slide, coated with 
palladium/gold and imaged by a scanning electron microscopy (Hitachi modelS-
4700).  
3.3.2.4 RNA replicon extraction from cross-linked particles particles 
 
For particles after cross-linking, 50 µL of PBS containing 10 mM DTT was 
added to dissolve 0.15mg particles. The particle solution should turn from cloudy 
to clear in no more than 3 min. After turning clear, the solution was further 
incubated at room temperature for 4 min before adding 200 µL of chloroform into 
the vial. A Qiazol-chloroform extraction procedure was then used to extract RNA 
replicon from the RNA replicon-BSA mixture following the procedures described 
in 3.2.2.5. The RNA replicon extracted out of particles was evaluated using 
Agarose gel electrophoresis and CAT ELISA assay as described in sections 
3.2.2.6 and 3.2.2.7. 
3.3.3 Results and discussion 
 
The stabilization of PRINT albumin particles in aqueous solutions was 
achieved by introducing DIC as the cross-linker (Figure 3.8). To assess the 
integrity of RNA replicon after cross-linking reaction, particles were dissolved in 
10mM DTT solution and the RNA replicon extracted from the mixture was 
evaluated by agarose gel electrophoresis (Figure 3.9). The agarose gel results 
showed that after the cross-linking reaction the RNA replicon inside protein 
particles was minimally affected. The RNA replicon integrity was also confirmed 
by induced expression of CAT pro
3.10).  Compared with untreated RNA replicon, the RNA replicon extracted out of 
cross-linked particles showed slight decrease in activity possibly due to the 
condition used to degrade particles, but a significa
RNA was still present in the particles.  
 
               
Figure 3.5 SEM image of DIC
replicon, image was taken after incubation with PBS, scale bar stands for 10 
 
                               
Figure 3.6 RNA replicon 
particle cross-linking: lane 1: RNA marker, 2: untreated RNA replicon 200ng, 3: 
untreated RNA replicon 100ng, 4: unt
extracted out of BSA particles before cross
extracted out of BSA particles after cross
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tein after transfection to Vero cells (Figure 
nt amount of intact and viable 
 
 
-cross-linked particles containing CAT RNA 
                               
characterization using Agarose gel before and after 
reated RNA replicon 50ng, 5: RNA replicon 
-linking reaction, 6: RNA replicon 
-linking reaction. 
µm.   
 
 Figure 3.7 RNA replicon integrity after crosslinking reaction evaluated by CAT 
ELISA. The absorbance from un
bars stand for standard deviation calculated from four wells. 
3.4 CBSA-Based particles for Delivery of RN
3.4.1 Introduction 
 
The cargo incorporation was optimized with normal un
the results indicated that lower temperature on the heated laminator is the key to 
maintaining the RNA integrity. The previous results also indicated that 
linking using DIC do not harm the activity of RNA replicons. However, the 
negatively charged normal BSA particles could not be internalized and 
transfected by cells. As previously mentioned, cationized BSA is one of the 
strategies used to overcom
RNA replicon particle is that the polycation and the polyanionic RNA replicons
tend to form strongly binded complexes which will be difficult to fill into the 
cavities.  Base on the study by Fischer D. et al.
medium can greatly affect the complex sizes and at high pHs above 9, there was 
no complex formation between the plasmid DNA and the cBSA.
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-treated cells (cells only) was defined as 1. Error 
 
A Replicon 
-modified BSA and 
e these issues. The main issue with making c
, the pH of the complexation 
5
 Herein, a high 
 
the cross-
BSA-
 
83 
pH solution strategy could be used to break the complexation between cBSA and 
RNA replicon.  
3.4.2 Experimental Section 
3.4.2.1 Materials 
 
CBSA was purchased from Thermo Scientific. TransIT®-mRNA 
transfection kit was purchased from Mirus. α-D-Lactose and glycerol were 
purchased from Acros. DIC was synthesized as described in section 2.3.2.2.  
3.4.2.2 Fabrication of cBSA/RNA replicon particles 
 
The cBSA PRINT particles were derived from a mixture composed of 37.0 
wt% of cBSA, 37.0 wt% of lactose, 25.0 wt% of glycerol and 1.0 wt% of RNA 
replicon (CAT). A 7.8 wt% solution of this mixture in a mixed medium (45% of 
water, 45% of trifluoroethanol and 10% of ammonium anhydride) was prepared 
and then cast a film onto a poly(ethylene terephthalate) (PET) sheet. Water was 
removed with a heat gun moving back and forth.  The film was laminated onto a 
piece of PRINT mold (2 × 4 inch, cylindrical, d =1µm, h = 1µm), forming a 
sandwich structure with the film in the middle. The mold was filled and the 
particles were harvested following procedures described in section 2.3.2.2. The 
particles were finally dispersed in isopropanol and the particle concentration was 
determined by Thermal Gravimetric Analysis (TGA) (TA Q5000). RNA replicon 
loaded Alexa fluor 555® labeled BSA particles were derived from a mixture 
composed of 36.7 wt% of cBSA, 37.0 wt% of lactose, 25.0 wt% of glycerol, 1.0 
wt% of RNA replicon and 0.3 wt% of Alexa-fluro-555 labeled BSA. 
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3.4.2.3 Cross-linking of the cBSA particles 
 
The particles were cross-linked following the procedures described in 
section 2.4.2.2 using a DIC cross-linker concentration of 4.4 mM in the final 
solution. The reaction was carried out for 24 h at 40 °C. 
3.4.2.4 Alexa fluor 488® labeled BSA particles for Confocal imaging 
 
Typically, 2×104 Vero cells were plated into 24 well tissue cultured treated 
plates 18-24 h prior to assay. The cells were dosed with cross-linked cBSA 
particles at 1 mg/mL concentration. After 4 h, Confocal images were acquired 
using a Ziess 710 laser scanning confocal imaging system (Olympus) 
fluorescence microscope fitted with a PlanApo 60× oil objective (Olympus).  The 
final composite images were created using Adobe Photoshop CS (Adobe 
Systems, San Jose, CA).  
3.4.2.5 Evaluation of cargo loading using agarose gel electrophoresis 
 
An agarose gel was prepared by dissolving agrasose in 1× 
NorthernMax®-Gly gel preparation and running buffer (Ambion) at 1 wt%.  
Typically, 5 µL of sample (particle solution without extraction) was mixed with 5 
µL of water and 10 µL of NorthernMax®-Gly load dye (Ambion) and heated at 50 
°C for 10 min before loading onto the gel. The gel was then run in 1× 
NorthernMax®-Gly gel preparation and running buffer (Ambion) at 70 V for 35 
min before being imaged by a GE ImageQuant LAS 4000 biomaolecular imager.  
3.4.2.6 Evaluation of RNA replicon activity through CAT expression 
 
Typically, 2×104 Vero cells were plated into 24 well tissue cultured treated 
plates 18-24 h prior to assay. Vero cells were transfected with CAT RNA replicon 
utilizing the TransIT® mRNA transfection kit (Mirus Bio, Madison, WI) following 
the manufacturer’s protocol. Cell lysates were prepared 48h post
and CAT ELISA (Roche, Indianapolis) analysis was carried out according to the 
manufacturer's instructions.
3.4.3 Results and Discussions
 
To determine replicon RNA encapsulation in cBSA particles and its 
subsequent release upon reducing reagents and salts, un
cross-linked particles were tested by gel e
cBSA RNA replicon-containing particles tested, no free RNA was detected 
indicating that RNA replicon was not released in its free form und
conditions (lane 5, Figure 3.8). This result suggested that the electrostatic 
interaction between the cationic BSA and RNA replicon is 
not allow the release of the cargo.
                                  
Figure 3.8 Agarose gel of RNA replicon 
replicon standard 1 µg, 2: blank cBSA
loaded with RNA replicon, 4: cross
replicon, 5: cross-linked cBSA particle loaded with RNA replicon treated with 10 
mM DTT and CaCl2 (500 mM)
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-crosslinked and DIC 
lectrophoresis (Figure 3.8). For all 
problematic
 
 
in cBSA particles. Lane 1: CAT RNA 
 particle, 3: un-cross-linked cBSA particle 
-linked cBSA particle loaded with RNA 
 
transfection 
er reducing 
 and does 
The internalization of cBSA 
Confocal imaging (Figure 3.9) The results indicated that normal BSA particles 
could not be taken up by cells whereas cBSA particles showed high 
internalization efficiency. 
Figure 3.9 Internalization of Alexa fl
cBSA particles (B), red: Alexa fluor 555
30 µm 
 
The RNA replicon-loaded cBSA particles were then dosed to Vero cells 
and RNA replicon mixed with a mRNA transfection reagent 
as positive controls (black bar in Figure 3.10). The amount of CAT protein 
generated by cells was measured using CAT ELISA. The CAT proteins were 
used as standards on ELISA (red bars in Figure 3.10).  The results indicated that 
there was no protein expression associated with cBSA particles loaded with CAT 
RNA replicon (orange bars in Figure 3.10). The failure could be due to 1) the 
integrity of the RNA replicon was disrupted by the high pH solution used to 
prepare pre-particle material, 2
was too strong, 3) the inability of the particles to escape the endosome. This 
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particles by Vero cells was evaluated using 
uor 555® labeled BSA particles
® labeled particles, scale bars represent 
TransIT
) complexation between RNA replicon and cBSA 
 
 (A) and 
 were used 
method was also accompanied by the difficulty of analyzing the RNA replicon 
integrity after incorporation into the cBSA particles.  
Figure 3.10 Absorbance obtained from CAT ELISA
 
3.5 Delivery of RNA Replicon via PRINT Protein
3.5.1 Introduction 
 
The previous results indicate that both the particle preparation from un
modified BSA and cross-linking 
But the cBSA-based particles could not deliver RNA replicons to Vero cells and 
that method was accompanied by difficulties to analyze the integrity of RNA 
replicons. Based on these results, we pursued the co
particles derived from normal BSA to cells. We first tried TransIT, the 
commercially available transfection reagent for mRNA, which we used to deliver 
RNA replicon as a positive control. 
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 on cBSA particles
-based Particles
using DIC do not harm the RNA replicon activity. 
ating strategy to deliver the 
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3.5.2 Experiment section 
3.5.2.1 Materials 
 
Bovine serum albumin and FluorsaveTM reagent were from Calbiochem. 
Alexa fluor 488® labeled Bovine serum albumin, Alexa Fluor® 546 goat anti-
rabbit IgG (H+L) was purchased from invitrogen. Anti-Chloramphenicol 
Acetyltransferase antibody was purchased from Abcam. TransIT®-mRNA 
transfection kit was purchased from Mirus. α-D-Lactose and glycerol were 
purchased from Acros. DIC and OEDIC were synthesized as previously 
described. Cells were cultured as previously described and CAT, GFP and 
Luciferase RNA replicons were prepared as previously described.  
3.5.2.3 Preparation of RNA replicon loaded particles 
 
CAT and Luciferase RNA replicon loaded Alexa fluor 488® labeled BSA 
particles were derived from a mixture composed of 36.7 wt% of BSA, 37.0 wt% of 
lactose, 25.0 wt% of glycerol, 1.0 wt% of CAT or Luciferase RNA replicon and 
0.3 wt% of Alexa-fluro-488® labeled BSA. GFP RNA replicon loaded particles 
were derived from a mixture composed of 37.0 wt% of BSA, 37.0 wt% of lactose, 
25.0 wt% of glycerol and 1.0 wt% of RNA replicon. 
3.5.2.4 Stabilization of RNA replicon loaded particles 
 
The stabilization of particles with the DIC cross-linker was performed as 
previously described in section 3.4.2.2. 
The particles were cross-linked with OEDIC by following similar 
procedures: Based on the TGA results, an appropriate amount of isopropanol 
was added to the particle dispersion to achieve a particle concentration of 
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1mg/mL. To 850 µL of particle dispersion, 1.096 mg of OEDIC (corresponding to 
4.4 mM in the final solution) was added. The resulting dispersion was shaken on 
a vortex machine for 24 h at 40 °C. The reaction was terminated and the particles 
were washed, aliquoted and stored as described in section 3.4.2.2  
3.5.2.5 Size and ζ potential characterization of the PRINT protein particles 
 
For ζ potential measurements, the particles were dispersed in 1 mM 
potassium chloride at a concentration of 4 µg/ml. For particles coated with 
TransIT, to 10 µL of Opti-MEM® I Reduced-Serum Medium, 2 µg of particles, 2 
µL of TransIT and 2 µL of boost were added and mixed through pipetting. The 
hydrodynamic diameters of the PRINT particles were measured by dynamic light 
scattering (Brookhaven Instruments Inc., 90Plus) and a Zetasizer Nano Analyzer 
(Malvern Instruments Inc., Nano Zetasizer).  
3.5.2.6 Analysis of CAT expression of PRINT BSA particles 
 
The expression of CAT protein from CAT replicon RNA or 1 µm BSA 
PRINT particles containing 1wt% CAT replicon RNA as cargo was compared. 
Typically, 2×104 Vero cells were plated into 24 well tissue cultured treated plates 
18-24 h prior to assay. Vero cells were transfected with CAT RNA replicon or 
PRINT BSA particles containing 1wt% CAT replicon RNA utilizing the TransIT® 
mRNA transfection kit (Mirus Bio, Madison, WI) following the manufacturer’s 
protocol. Briefly, to 100 µL of Opti-MEM® I Reduced-Serum Medium, particle 
solution containing 50 µg, 10 µg, 5 µg, 2 µg, 1 µg, 500 ng, 250 ng of particles, 2 
µL of TransIT and 1 µL of boost were added and mixed through pipetting. The 
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mixture was subsequently incubated with Vero cells for 4 h at 37 °C and the non-
internalized particles were removed. The cells were further incubated for another 
48 h at 37 °C to allow CAT protein to express. Cell l ysates were prepared 48h 
post-transfection and CAT ELISA (Roche, Indianapolis) analysis was carried out 
according to the manufacturer's instructions. The amount of CAT protein 
generated was calculated based on a standard curve from 2, 1, 0.5, 0.25, 0.125 
and 0 ng/mL of CAT protein.  
3.5.2.7 Immunofluorescence Microscopy 
 
Vero cells plated at on cover slips in 6-well dishes and grown for 24 hours. 
Cells were treated with particles for 48 h.  Cells were then washed with PBS and 
fixed with 4% Para formaldehyde in PBS for 10min at room temperature.  Cells 
were permeablized with 0.1% triton –X100 in PBS for 3min and incubated and 
washed in PBS for 3 times. Samples were then blocked in 5% normal serum in 
1%BSA/ 0.2% triton X -100/ PBS overnight at 4 °C.  Cells were then incubated in 
primary antibody abcam (CAT#ab50151) for 1 hr at room temperature, cells were 
then washed with PBS and incubated in secondary Alexa Fluor® 546 goat anti-
rabbit IgG (H+L)  (A11010, invitrogen) for 1hr at RT in dark. Washed twice in 
PBS and mounted with FluorsaveTM reagent. Samples were then analyzed by 
confocal microscopy. Confocal images were acquired using a Ziess 710 laser 
scanning confocal imaging system (Olympus) fluorescence microscope fitted with 
a PlanApo 60× oil objective (Olympus).  The final composite images were 
created using Adobe Photoshop CS (Adobe Systems, San Jose, CA).  
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3.5.2.8 Analysis of Luciferase expression and GFP expression 
 
Typically, 2×104 Vero cells were plated into 24 well tissue cultured treated 
plates 18-24 h prior to assay. Vero cells were transfected with Luciferase or GFP 
RNA replicon or PRINT BSA particles containing Luciferase or GFP replicon 
RNA utilizing the TransIT® mRNA transfection kit (Mirus Bio, Madison, WI) 
following the manufacturer’s protocol. Briefly, to 100 µL of Opti-MEM® I 
Reduced-Serum Medium, 2 µg, 1 µg, 500 ng or 250 ng of particles, 2 µL of 
TransIT and 1 µL of boost were added and mixed through pipetting. The mixture 
was subsequently incubated with Vero cells for 4 h at 37 °C and the non-
internalized particles were removed. The cells were further incubated for another 
24 h at 37 °C to allow Luciferase or GFP protein to e xpress. Cell lysates were 
prepared 24h post-transfection and Luciferase assay was carried out according 
to the manufacturer's instructions. Cells expressing GFP were imaged using a 
Ziess 710 laser scanning confocal imaging system (Olympus) fluorescence 
microscope fitted with a PlanApo 60× oil objective (Olympus). 
3.5.3 Results and discussion 
 
Due to the isoelectric point of BSA (pI = 4.75), the cross-linked BSA 
particles with RNA replicons were found to be negatively charged (ζ potential = -
15.4 ± 1.0 mV). Based on the previous studies from our group and other groups, 
cells generally preferentially internalize positively charged particles through a 
non-specific electrostatic interactions between the positively charged particles 
and the negatively charged cell membrane.22 Our confocal microscopy studies 
confirmed that negatively charged BSA particles did not show significant cell 
uptake (Figure 3.6). In order to introduce positive charges to BSA particle surface 
to enhance cell uptake, a certain amount of TransIT was mixed with BSA 
particles. The introduction of TransIT is also expected to enhance 
escape of BSA particles, which is the major roadblock for RNA replicon delivery. 
The cross-linked particles mixed with TransIT achieved a positively charged 
particle surface (ζ potential = + 0.8 
with Vero cells for 4 h at 37 
(Table 3.2)  Confocal microscopy studies showed that particles coated with 
TransIT were internalized by Vero cells (Figure 3.11
 
Table 3.2 aCharacterization of cross
 Diameter, nm
Without TransIT 1214 
With TransIT 1179 
a
 The particles charged with 1 wt% of CAT RNA replicon.  The particles (2 
were added into 10 µL (Opti
boost and 2µL of TransIT were added subsequently. The reaction went for 5 min 
before measurements were taken.
 
                                 
Figure 3.11 Confocal microscopy of Vero cells dosed wit
particles, RNA replicon-
represents 30 µm. 
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the endosomal 
± 0.3 mV) and were subsequently incubated 
°C and the non- internalized particles were removed
). 
-linked particles with and without TransIT 
 PDI  ζ-Potential, mV
± 483 0.159 -15.4 
± 721 0.374  + 0.8 
-MEM® I Reduced-Serum Medium), and then 1
 
 
h PRINT protein 
containing BSA particles with TransIT, scale bar 
. 
 
 
± 1.0 
± 0.3 
µg) 
 µL of 
93 
The cells were further incubated for another 48 h at 37 °C to allow CAT 
protein to express. The CAT protein generated via delivery of PRINT particles 
was comparable to the same amount of RNA replicon directly delivered by 
TransIT (Figure 3.12). As a negative control, blank particles with no RNA replicon 
encapsulated didn’t induce any protein expression. However, it was possible that 
the protein expression might be induced by RNA replicon that passively released 
from protein particles through diffusion and transfected by TransIT. To 
investigate this possibility, DIC-cross-linked BSA particles containing CAT RNA 
replicon were incubated in PBS for 4 h at 37 °C, which is the dosing condition for 
the RNA replicon delivery studies, and pelleted down through centrifugation. The 
supernatant was dosed to cells with TransIT and no protein expression was 
observed. This result confirmed that RNA replicon was physically entrapped in 
the BSA particles and was released in the cytoplasm of Vero cells, where CAT 
protein was expressed.  
To study the necessity of a disulfide cross-linker in the delivery of RNA 
replicon via protein particles, particles cross-linked with the non-degradable linker 
2,2'-oxybis(ethane-2,1-diyl) bis(1H-imidazole-1-carboxylate) (OEDIC) under the 
same reaction condition as DIC was also investigated (Figure 3.13). Because 
both DIC and OEDIC have imidazoles as the leaving groups and the 
concentrations of crosslinkers and the reaction time are the same, we expect 
BSA particles crosslinked with DIC and OEDIC have similar cross-linking density. 
It was observed that very minimal protein was expressed with particles cross-
linked by OEDIC compared to particles cross-linked by the disulfide cross-linker 
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DIC. This result demonstrated that 1) a disulfide linker is important to achieve 
cytoplasm release of RNA replicon; 2) the intracellular protease were not 
responsible for the BSA particle degradation and RNA replicon release at least 
during the 48-h time frame of our assay; and 3) passive release of RNA replicon 
through diffusion contributed little to the observed biological activity. Therefore, 
the disulfide linker DIC can not only stabilize particles in the process of delivery, 
but also efficiently release RNA replicon at the ultimate site of action.   
 
Figure 3.12 CAT protein generated from Vero cells (2×104 cells per well) 
measured by ELISA. Black: CAT RNA standards with TransIT, purple: blank 
particles with TransIT, orange: CAT RNA containing BSA particles with TransIT, 
2, 1 and 0.5μg/mL of particles corresponds to 30, 15 and 7.5 ng/mL of RNA (SI), 
blue: supernatant from particles incubated in PBS for 4 h at 37°C with TransIT. 
Error bars represent standard deviation calculated from four wells. 
 
                        
Figure 3.13 SEM image of OEDIC
replicon, scale bar represents 5 
 
Analysis using confocal microscopy was carried out to visually confirm the 
generation of CAT protein. Vero cells treated with BSA particles containing RNA 
replicon were further treated with a primary antibody that binds specifically to 
CAT protein, and further treated with dye
to untransfected cells, cells transfected with DIC
containing particles showed intense fluorescence, indicating for high levels of 
expression of CAT proteins in those cells (Figure 3.14
negative control showed no trace of CAT protein.
Figure 3.14 Confocal image of CAT protein
replicon with TransIT, (B) blank particles, 2 
CAT RNA replicon cross-linked with DIC, 2 
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-crosslinked particles containing CAT RNA 
µm.   
-labeled secondary antibody. Compared 
-cross-linked RNA replicon
). Blank particles as a 
 
 (40×). (A) 100 ng of CAT 
µg/mL. (C) BSA particles containing 
µg/mL. 
-
RNA 
An issue with the TransIT coated particles is the lack of dependence of 
protein expression on particle amount. At particl
µg/mL, protein expression drops with increased particle concentration (Figure 
3.15) The particle uptake by Vero cells was evaluated using flow cytometry and 
Confocal imaging. The internalization efficiency started to drop at higher particle 
concentrations and the confocal imaging study indicated that particles showed 
aggregation at a particle concentration of 50 
 
  
Figure 3.15 Absorbance from CAT ELISA
delivered by TransIT, purple: blank particles, yellow
particles containing CAT RNA
solution only and cells only
 
            
Figure 3.16 Particle internalization characterized by flow cytometry
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e concentrations higher than 2 
µg/mL.  
. Black: CAT RNA replicon standards 
: DIC-cross-
 replicon, red: CAT protein standards, bl
 
 
 
 
linked BSA 
ue: 
 Figure 3.17 Particle internalization after 24 h, characterized by Confocal imaging 
(A) 2 µg/mL, (B) 50 µg/mL, green: Alexa fluoro 488 la
 
To show that RNA replicons encoding different proteins can be 
encapsulated and delivered within the same PRINT protein particle, RNA 
replicons encoding Luciferase and GFP were incorporated into BSA
particles and delivered to Vero cel
generated via delivery of PRINT particles was comparable to the same amount of 
RNA replicon directly delivered by TransIT (Figure 3.18
generated by PRINT particles containing GFP RNA replicon
fluorescent microscope, indicating successful delivery of GFP RNA repli
the Vero cells (Figure 3.19
molding therapeutics with straightforward incorporation of different cargos
can work in a “plug and play” manner, which is particularly important for 
development of new vaccines for epidemic diseases.
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beled particles 
ls with TransIT. The Luciferase protein 
). The green fluorescence 
s was observed with 
). These results suggested that PRINT is a platform for 
 
 
-based 
con to 
 and 
Figure 3.18 Relative Luminesence generated by Luciferase encoded by PRINT 
particles. Blue: cells only, Black: CAT RNA replicon standards delivered by 
TransIT, purple: DIC-crosslinked BSA particles containing Luciferase RNA 
replicon, Error bars represent standard devi
 
 
                   
Figure 3.19 Fluorescence generated from GFP encoded by RNA replicon 
delivered by PRINT particles. GFP RNA replicon delivered by PRINT particles. 
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ation calculated from four wells. 
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3.6 In vivo efficacy of PRINT Particles for Luciferase RNA Replicon 
Delivery 
3.6.1 Experiment section 
3.6.1.1 Materials 
 
Bovine serum albumin was from Calbiochem. Alexa fluor 488® labeled 
Bovine serum albumin was purchased from invitrogen. TransIT®-mRNA 
transfection kit was purchased from Mirus. α-D-Lactose and glycerol were 
purchased from Acros. DIC was synthesized as previously described. Luciferase 
RNA replicons were prepared as previously described.  
All mice were handled in accordance with the University of North 
Carolina’s Institutional Animal Care and Use Committee (IACUC) protocols. 
Balb/c Nude mice were purchased from Harlan Labs and quarantined for two 
weeks before being treated with naked Luciferase RNA replicon or PRINT BSA 
particles. 
3.6.1.2 Preparation of RNA replicon loaded particles 
 
Luciferase RNA replicon loaded Alexa fluor 488® labeled BSA particles 
were derived from a mixture composed of 36.7 wt% of BSA, 37.0 wt% of lactose, 
25.0 wt% of glycerol, 1.0 wt% of Luciferase RNA replicon and 0.3 wt% of Alexa-
fluro-488® labeled BSA. The stabilization of particles with cross-linker DIC was 
performed as previously described in section 3.3.2.2. 
3.6.1.3 Injection  
 
All mice were injected through subcutaneous route on the left footpad 
using syringes (3/10cc insulin syringe U-100 29G ½”).  
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Table 3.3 Dose information for in vivo efficacy study 
 
Dose Description 
 
Concentration Dose Volume for 
each group  
Luci-RNA a  0.1 mg/mL 20µL × 3 
Luci-RNA with TransITb 0.1 mg/mL 20µL × 3 
Luci-RNA Particle with TransITc 10 mg/mL, 5 mg/mL 20µL × 3 
Luci-RNA particlesd 10 mg/mL, 5 mg/mL 20µL × 3 
a RNA replicon in naked form, b 2 µg of RNA replicon dosed with 50 µL of TransIT 
and 25 µL of boost, c For 10 mg/mL of particles, 200 µg of particles were dosed 
with 50 µL of TransIT and 25 µL of boost and for 5 mg/mL of particles, 100 µg of 
particles were dosed with 25 µL of TransIT and 12.5 µL of boost , d Particles only 
were dosed to the mice.  
 
3.6.1.4 Imaging 
 
All mice will be imaged at 24-h time point. Imaging of mice followed the 
same order for injection. Prior to imaging, each mouse was injected i.p. with 
potassium luciferin substrate, a suggested dose being 200 µL of a 15 mg/mL 
solution.  Imaging of animals took place immediately after luciferin substrate 
injection.  Animals were imaged in both the prone and supine positions using an 
IVIS Lumina imaging system. 
3.6.2 Results and discussion 
 
As previously mentioned, in vivo immunity has been achieved in mice 
through direct intramuscular injection.23 In this study, mice injected with naked 
RNA replicon in the footpad showed in vivo expression of Luciferase protein.  
However, when the naked RNA replicon is injected with TransIT, there was no 
protein generated. TransIT as a mRNA transfection reagent has never been 
reported for use in vivo and this results indicated that it may have some inhibiting 
effect on the in vivo transfection of RNA replicon. The T
mg/mL and 5 mg/mL, 5 mg/mL not shown) and particles only
and 5 mg/mL, 5 mg/mL not shown) showed no Luciferase expression, indicating 
that another transfection reagent different from TransIT is needed to achieve the 
in vivo delivery of these particles.  Another disadvantage with TransIT is that it is 
not possible to find out the detailed information about its structure which is 
essential to design experiments to further improve the delivery efficacy. 
 
                
Figure 3.17 Bioluminescence imaging of mice injected with naked luciferase 
RNA replicon (A), luciferase RNA replicon with TransIT (B), particles with TransIT 
(C), particles only (D). 
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3.7 Particle Transfection with Cationic Lipids 
3.7.1 Introduction 
 
The aforementioned issues with TransIT as coating agent for the PRINT 
BSA particles and failure to achieve in vivo protein expression motivated us to 
find another reagent that can facilitate cell uptake and transfection in vivo. 
DOTAP and DOPE have been widely used as transfection reagents for gene 
delivery and they also enjoy the advantage of being cost-effective and 
commercially available. 13,14, 24 
3.7.2 Experimental section 
3.7.2.1 Materials 
 
1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) (DOTAP), 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and Transfection Reagent I, 
contains DOTAP:DOPE (1:1 w/w) in powder forms were from Avanti polar lipids, 
Inc.  
3.7.2.2 Preparation of lipid solutions 
 
Transfection reagent I (5 mg) was first dissolved in 50 µL of 
trifluoroethanol (TFE) and then 1.616 mL of DEPC-treated water was added to 
achieve a concentration of 3 mg/mL, which was further diluted with water to 
achieve concentrations of 2, 1, 0.5, 0.25 and 0.1 mg/mL.  
DOTAP solution (3 mg/mL) was prepared by first dissolving DOTAP (1 mg) 
in 20 µL of TFE and adding 310 µL of water. The 3 mg/mL of DOTAP was further 
diluted to concentrations of 2, 1, and 0.5 mg/mL.  
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DOTAP:DOPE (75:25) and DOTAP:DOPE (25:75) were prepared by first 
dissolving 1 mg of DOTAP and 1 mg of DOPE in 20 µL of TFE separately and 
mixing the two components according to the above ratio. Then water was added 
to achieve a concentration of 3 mg/mL which was further diluted to 
concentrations of 2, 1, and 0.5 mg/mL.  
3.7.2.3 Particle complexed with lipids  
 
Particles were prepared and cross-linked as previously described and 
were resuspended in isopropanol at 1 mg/mL. Particles were pelleted down using 
a minicentrifuge for 30 seconds. Isopropanol was then removed. Lipid solution 
were added to the vial to achieve a particle concentration of 1mg/mL and mixed 
by pippeting. The solution was incubated at room temperature for 1 hour. The 
particles were pelleted down using a minicentrifuge for 1 minute and then 
supernatant was removed. The same amount of water was added to the vial to 
achieve a particle concentration of 1mg/mL and the then dispersed by pippeting.  
3.7.2.4 Particle characterization and measurement of luciferase expression 
 
Particles were characterized as previously described in section 3.5.2.4. 
Luciferase protein expression was analyzed as previously described in section 
3.5.2.7.  
The amount of lipid comlexed with particles were characterized using 
HPLC-ELSD method. The amounts of DOTAP and DOPE were measured using 
HPLC (Agilent Technologies 1260) with a C18 rapid resolution column (Zorbax 
Eclipse plus, 4.6 × 100 mm, 3.5 micron).  A mobile phase of water and methanol 
on a gradient from 15% of water to pure methanol over 15 minutes with a flow 
rate of 0.6 mL/min was employed with a detection temperature of 50 
ELSD (Agilent Technologies 1260).
were calculated by subtracting
solutions from the original lipid solution and then comparing to standard curves
3.7.3 Results and discussion
 
The cross-linked particles mixed with 
positively charged particle surface (
DLS showed particle aggregation at lower lipid to particle ratios and no 
aggregation at higher lipid concentrations.
        
Figure 3.21 Zeta potential and particle size as a fun
(DOTAP:DOPE=1:1)  to particles ratio (wt:wt)
 
The particles coated with different lipid formulations (concentration of lipid 
used to coat particles, lipid composition) were then dosed to Vero cells and 
Luciferase protein expression was analyzed (Figure 3.22). The results 
that the TansIT/particle formulation was outperformed by particles incubated with 
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 The amount of lipid complexed with particles 
 amount of lipid in the supernatant and washing 
 
DOTAP and DOPE lipids
Figure 3. 21). The particle size measured by 
 
 
ction of lipid 
 
°C on the 
.  
 achieved a 
indicated 
2 mg/mL and 3 mg/mL of DOTAP solutions, as well as 2 mg/mL and 3 mg/mL of 
DOTAP:DOPE (75:25) solutions at a particle concentration of 
The lipid-complexed
transfection. It was found that 
(75:25) solutions and washed three times to remove residual lipids were the best 
performing formulation for 
HPLC-ELSD results, , 0.46 ± 0.06 mg of DOTAP and 0.11 ±0.02 mg of
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3.8 Conclusions and Future Work
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technology platform, not only allows for the fabrication of particles of controlled 
sizes and shapes, but also was gentle and RNA replicon could be encapsulated 
in the particles without abolishing their biological activities.  A disulfide cross-
linker was used to stabilize the particles in aqueous solutions. The disulfide 
cross-linker was demonstrated to be RNA-friendly and stabilized the particles 
without affecting the biological performance of RNA replicons. By coating the 
particles with TransIT, the particles were delivered to Vero cells and CAT protein 
was expressed via delivery of PRINT particles. The reversible disulfide linker was 
demonstrated to play a vital role in the successful delivery of RNA replicon. RNA 
replicons encoding different proteins including Luciferase and GFP were 
incorporated into the PRINT particles and delivered using the same strategy. A 
cationic lipid strategy was also developed to facilitate cell uptake and particle 
transfection. Investigation of in vivo delivery efficiency and immunogenicity is 
also underway. The future work will focus on RNA replicons encoding proteins 
that will serve as antigens, trigger production of antibodies and improve immunity 
towards diseases.  
In addition to the cationic lipids which is currently under investigation, the 
following strategies can also be explored to facilitate the internalization and 
transfection of protein-based particles: 
1) Cell penetrating peptides (CPPs). CPPs such as TAT peptide are short 
peptides that are able to transport different cargo molecules across plasma 
membrane and directly to the cytoplasm of cells. This characteristic has been 
regarded a highly promising strategy to deliver numerous drugs and cargos and 
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the protein particles with CPPs on the surface may be translocated to the 
cytoplasm efficiently where the RNA replicon can be released and encode for 
antigens.  
2) Cationic polymer conjugated with fusogenic peptides or histidine-rich 
peptides, e.g., H5WYG, KALA, ppTG1, etc. The cationic polymer can potentially 
bind to the surface of the negatively charged particles due to electrostatic 
interactions and facilitate cell uptake and the peptides may help break the 
endosome after the particles are internalized.   
In summary, the PRINT technology allows for fabrication of protein 
particles with the ability to encapsulate therapeutics in an easy and gentle way, 
showing the first non-viral delivery for RNA replicon and great promise as a 
highly tunable drug delivery system. 
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